US20050124583A1 - Prodrugs of phosphonate nucleotide analogues - Google Patents

Prodrugs of phosphonate nucleotide analogues Download PDF

Info

Publication number
US20050124583A1
US20050124583A1 US11/031,250 US3125005A US2005124583A1 US 20050124583 A1 US20050124583 A1 US 20050124583A1 US 3125005 A US3125005 A US 3125005A US 2005124583 A1 US2005124583 A1 US 2005124583A1
Authority
US
United States
Prior art keywords
ch
gs
pmpa
kg
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/031,250
Inventor
Mark Becker
Harlan Chapman
Tomas Clhlar
Eugene Elsenberg
Gong-Xin He
Michael Kernan
William Lee
Ernest Prisbe
John Rohloff
Mark Sparacino
Original Assignee
Becker Mark W.
Chapman Harlan H.
Tomas Clhlar
Elsenberg Eugene J.
Gong-Xin He
Kernan Michael R.
Lee William A.
Prisbe Ernest J.
Rohloff John C.
Sparacino Mark L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US22002100P priority Critical
Priority to US09/909,560 priority patent/US20020119443A1/en
Priority to US10/354,207 priority patent/US20030219727A1/en
Priority to US10/798,692 priority patent/US7390791B2/en
Application filed by Becker Mark W., Chapman Harlan H., Tomas Clhlar, Elsenberg Eugene J., Gong-Xin He, Kernan Michael R., Lee William A., Prisbe Ernest J., Rohloff John C., Sparacino Mark L. filed Critical Becker Mark W.
Priority to US11/031,250 priority patent/US20050124583A1/en
Publication of US20050124583A1 publication Critical patent/US20050124583A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22821718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050124583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Abstract

A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a)
Figure US20050124583A1-20050609-C00001
having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Description

    1. CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of Ser. No. 10/798,692, filed Mar. 11, 2004, now pending, which is a continuation of Ser. No. 10/354,207, filed Jan. 28, 2003, now pending, which is a continuation of Ser. No. 09/909,560, filed Jul. 20, 2001, now abandoned, which claims benefit under 35 U.S.C. § 119(e) to Ser. No. 60/220,021, filed Jul. 21, 2000, all of which are incorporated herein by reference.
  • 2. FIELD
  • This application relates to prodrugs of methoxyphosphonate nucleotide analogues. In particular it relates to improved methods for making and identifying such prodrugs.
  • Many methoxyphosphonate nucleotide analogues are known. In general, such compounds have the structure A-OCH2P(O)(OR)2 where A is the residue of a nucleoside analogue and R independently is hydrogen or various protecting or prodrug functionalities. See U.S. Pat. Nos. 5,663,159, 5,977,061 and 5,798,340, Oliyai et al, “Pharmaceutical Research” 16(11):1687-1693 (1999), Stella et al., “J. Med. Chem.” 23(12):1275-1282 (1980), Aarons, L., Boddy, A. and Petrak, K. (1989) Novel Drug Delivery and Its Therapeutic Application (Prescott, L. F. and Nimmo, W. S., ed.), pp. 121-126; Bundgaard, H. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 70-74 and 79-92; Banerjee, P. K. and Amidon, G. L. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 118-121; Notari, R. E. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 135-156; Stella, V. J. and Himmelstein, K. J. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 177-198; Jones, G. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 199-241; Connors, T. A. (1985) Design of Prodrugs (Bundgaard, H., ed.) pp. 291-316. All literature and patent citations herein are expressly incorporated by reference.
  • 3. SUMMARY OF THE INVENTION
  • Prodrugs of methoxyphosphonate nucleotide analogues intended for antiviral or antitumor therapy, while known, traditionally have been selected for their systemic effect. For example, such prodrugs have been selected for enhanced bioavailability, i.e., ability to be absorbed from the gastrointestinal tract and converted rapidly to parent drug to ensure that the parent drug is available to all tissues. However, applicants now have found that it is possible to select prodrugs that become enriched at therapeutic sites, as illustrated by the studies described herein where the analogues are enriched at localized focal sites of HIV infection. The objective of this invention is, among other advantages, to produce less toxicity to bystander tissues and greater potency of the parental drug in tissues which are the targets of therapy with the parent methoxyphosphonate nucleotide analogue.
  • Accordingly, pursuant to these observations, a screening method is provided for identifying a methoxyphosphonate nucleotide analogue prodrug conferring enhanced activity in a target tissue comprising:
      • (a) providing at least one of said prodrugs;
      • (b) selecting at least one therapeutic target tissue and at least one non-target tissue;
      • (c) administering the prodrug to the target tissue and to said at least one non-target tissue; and
      • (d) determining the relative antiviral activity conferred by the prodrug in the tissues in step (c).
  • In preferred embodiments, the target tissue are sites where HIV is actively replicated and/or which serve as an HIV reservoir, and the non-target tissue is an intact animal. Unexpectedly, we found that selecting lymphoid tissue as the target tissue for the practice of this method for HIV led to identification of prodrugs that enhance the delivery of active drug to such tissues.
  • A preferred compound of this invention, which has been identified by this method has the structure (1),
    Figure US20050124583A1-20050609-C00002
      • where Ra is H or methyl,
      • and chirally enriched compositions thereof, salts, their free base and solvates thereof.
  • A preferred compound of this invention has the structure (2)
    Figure US20050124583A1-20050609-C00003
      • and its enriched diasteromers, salts, free base and solvates.
  • In addition, we unexpectedly found that the chirality of substituents on the phosphorous atom and/or the amidate substituent are influential in the enrichment observed in the practice of this invention. Thus, in another embodiment of this invention, we provide diastereomerically enriched compounds of this invention having the structure (3)
    Figure US20050124583A1-20050609-C00004
      • which are substantially free of the diastereomer (4)
        Figure US20050124583A1-20050609-C00005
      • wherein
      • R1 is an oxyester which is hydrolyzable in vivo, or hydroxyl;
      • B is a heterocyclic base;
      • R2 is hydroxyl, or the residue of an amino acid bonded to the P atom through an amino group of the amino acid and having each carboxy substituent of the amino acid optionally esterified, but not both of R1 and R2 are hydroxyl;
      • E is —(CH2)2—, —CH(CH3)CH2—, —CH(CH2F)CH2—, —CH(CH2OH)CH2, —CH(CH═CH2)CH2—, —CH(C≡CH)CH2—, —CH(CH2N3)CH2—,
        Figure US20050124583A1-20050609-C00006

        —CH(R6)OCH(R6′)—, —CH(R9)CH2O—or —CH(R8)O—, wherein the right hand bond is linked to the heterocyclic base;
      • the broken line represents an optional double bond;
      • R4 and R5 are independently hydrogen, hydroxy, halo, amino or a substituent having 1-5 carbon atoms selected from acyloxy, alkyoxy, alkylthio, alkylamino and dialkylamino;
      • R6 and R6′ are independently H, C1-C6 alkyl, C1-C6 hydroxyalkyl, or C2-C7 alkanoyl;
      • R7 is independently H, C1-C6 alkyl, or are taken together to form —O— or —CH2—;
      • R8 is H, C1-C6 alkyl, C1-C6 hydroxyalkyl or C1-C6 haloalkyl; and
      • R9 is H, hydroxymethyl or acyloxymethyl;
      • and their salts, free base, and solvates.
  • The diastereomers of structure (3) are designated the (S) isomers at the phosphorus chiral center.
  • Preferred embodiments of this invention are the diastereomerically enriched compounds having the structure (5a)
    Figure US20050124583A1-20050609-C00007
      • which is substantially free of diastereomer (5b)
        Figure US20050124583A1-20050609-C00008
      • wherein
      • R5 is methyl or hydrogen;
      • R6 independently is H, alkyl, alkenyl, alkynyl, aryl or arylalkyl, or R6 independently is alkyl, alkenyl, alkynyl, aryl or arylalkyl which is substituted with from 1 to 3 substituents selected from alkylamino, alkylaminoalkyl, dialkylaminoalkyl, dialkylamino, hydroxyl, oxo, halo, amino, alkylthio, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylalkoxyalkyl, haloalkyl, nitro, nitroalkyl, azido, azidoalkyl, alkylacyl, alkylacylalkyl, carboxyl, or alkylacylamino;
      • R7 is the side chain of any naturally-occurring or pharmaceutically acceptable amino acid and which, if the side chain comprises carboxyl, the carboxyl group is optionally esterified with an alkyl or aryl group;
      • R11 is amino, alkylamino, oxo, or dialkylamino; and
      • R12 is amino or H;
      • and its salts, tautomers, free base and solvates.
  • A preferred embodiment of this invention is the compound of structure (6), 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine, also designated herein GS-7340.
    Figure US20050124583A1-20050609-C00009
  • Another preferred embodiment of this invention is the fumarate salt of structure (5) (structure (7)), 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate (1:1), also designated herein GS-7340-2
    Figure US20050124583A1-20050609-C00010
  • The compounds of structures (1)-(7) optionally are formulated into compositions containing pharmaceutically acceptable excipients. Such compositions are used in effective doses in the therapy or prophylaxis of viral (particularly HIV or hepadnaviral) infections.
  • In a further embodiment, a method is provided for the facile manufacture of 9-[2-(phosphonomethoxy)propyl]adenine (hereinafter “PMPA” or 9-[2-(phosphonomethoxy)ethyl]adenine (hereinafter “PMEA”) using magnesium alkoxide, which comprises combining 9-(2-hydroxypropyl)adenine or 9-(2-hydroxyethyl)adenine, protected p-toluenesulfonyloxymethylphosphonate and magnesium alkoxide, and recovering PMPA or PMEA, respectively.
  • 4. BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows HPLC/C-14 traces of PBMC extracts from human blood incubated for 1 h at 37° C. with TDF, GS-7340 and PMPA.
  • FIG. 2 shows PMPA and Prodrug concentration in plasma and PBMCs following oral administration of GS 7340-2 to Dogs at 10 mg-eq/kg.
  • FIG. 3 depicts Tenofovir exposure in PBMCs and plasma upon administration of 10 mg-eq/kg in dogs.
  • 5. DETAILED DESCRIPTION OF THE INVENTION
  • The methoxyphosphonate nucleotide analogue parent drugs for use in this screening method are compounds having the structure A-OCH2P(O)(OH)2 wherein A is the residue of a nucleoside analogue. These compounds are known
    Figure US20050124583A1-20050609-C00011

    per se and are not part of this invention. More particularly, the parent compounds comprise a heterocyclic base B and an aglycon E, in general having the structure wherein the group B is defined below and group E is defined above. Examples are described in U.S. Pat. Nos. 4,659,825, 4,808,716, 4,724,233, 5,142,051, 5,130,427, 5,650,510, 5,663,159, 5,302,585, 5,476,938, 5,696,263, 5,744,600, 5,688,778, 5,386,030, 5,733,896, 5,352,786, and 5,798,340, and EP 821,690 and 654,037.
  • The prodrugs for use in the screening method of this invention are covalently modified analogues of the parent methoxyphosphonate nucleotide analogues described in the preceding paragraph. In general, the phosphorus atom of the parent drug is the preferred site for prodrug modification, but other sites are found on the heterocyclic base B or the aglycon E. Many such prodrugs are already known. Primarily, they are esters or amidates of the phosphorus atom, but also include substitutions on the base and aglycon. None of these modifications per se is part of this invention and none are to be considered limiting on the scope of the invention herein.
  • The phosphorus atom of the methoxyphosphonate nucleotide analogues contains two valences for covalent modification such as amidation or esterification (unless one phosphoryl hydroxyl is esterified to an aglycon E hydroxyl substituent, whereupon only one phosphorus valence is free for substitution). The esters typically are aryloxy. The amidates ordinarily are naturally occurring monoamino acids having free carboxyl group(s) esterified with an alkyl or aryl group, usually phenyl, cycloalkyl, or t-, n- or s-alkyl groups. Suitable prodrugs for use in the screening method of this invention are disclosed for example in U.S. Pat. No. 5,798,340. However, any prodrug which is potentially believed to be capable of being converted in vivo within target tissue cells to the free methoxyphosphonate nucleotide analogue parent drug, e.g., whether by hydrolysis, oxidation, or other covalent transformation resulting from exposure to biological tissues, is suitable for use in the method of this invention. Such prodrugs may not be known at this time but are identified in the future and thus become suitable candidates available for testing in the method of this invention. Since the prodrugs are simply candidates for screening in the methods their structures are not relevant to practicing or enabling the screening method, although of course their structures ultimately are dispositive of whether or not a prodrug will be shown to be selective in the assay.
  • The pro-moieties bound to the parent drug may be the same or different. However, each prodrug to be used in the screening assay will differ structurally from the other prodrugs to be tested. Distinct, i.e. structurally different, prodrugs generally are selected on the basis of either their stereochemistry or their covalent structure, or these features are varied in combination. Each prodrug tested, however, desirably is structurally and stereochemically substantially pure, else the output of the screening assay will be less useful. It is of course within the scope of this invention to test only a single prodrug in an individual embodiment of the method of this invention, although typically then one would compare the results with prior studies with other prodrugs.
  • We have found that the stereochemistry of the prodrugs is capable of influencing the enrichment in target tissues. Chiral sites are at the phosphorus atom and are also found in its substituents. For example, amino acid used in preparing amidates may be D or L forms, and the phosphonate esters or the amino acid esters can contain chiral centers as well. Chiral sites also are found on the nucleoside analogue portion of the molecules, but these typically are already dictated by the stereochemistry of the parent drug and will not be varied as part of the screen. For example the R isomer of PMPA is preferred as it is more active than the corresponding S isomer. Typically these diasteromers or enantiomers will be chirally enriched if not pure at each site so that the results of the screen will be more meaningful. As noted, distinctiveness of stereoisomers is conferred by enriching or purifying the stereoisomer (typically this will be a diastereomer rather than an enantiomer in the case of most methoxyphosphonate nucleotide analogues) free of other stereoisomers at the chiral center in question, so that each test compound is substantially homogeneous. By substantially homogeneous or chirally enriched, we mean that the desired stereoisomer constitutes greater than about 60% by weight of the compound, ordinarily greater than about 80% and preferably greater than about 95%.
  • 5.1 Novel Screening Method
  • Once at least one candidate prodrug has been selected, the remaining steps of the screening method of this invention are used to identify a prodrug possessing the required selectivity for the target tissue. Most conveniently the prodrugs are labeled with a detectable group, e.g. radiolabeled, in order to facilitate detection later in tissues or cells. However, a label is not required since other suitable assays for the prodrug or its metabolites (including the parent drug) can also be employed. These assays could include mass spectrometry, HPLC, bioassays or immunoassays for instance. The assay may detect the prodrug and any one or more of its metabolites, but preferably the assay is conducted to detect only the generation of the parent drug. This is based on the assumption (which may not be warranted in all cases) that the degree and rate of conversion of prodrug to antivirally active parent diphosphate is the same across all tissues tested. Otherwise, one can test for the diphosphate.
  • The target tissue preferably will be lymphoid tissue when screening for prodrugs useful in the treatment of HIV infection. Lymphoid tissue will be known to the artisan and includes CD4 cells, lymphocytes, lymph nodes, macrophages and macrophage-like cells including monocytes such as peripheral blood monocytic cells (PBMCs) and glial cells. Lymphoid tissue also includes non-lymphoid tissues that are enriched in lymphoid tissues or cells, e.g. lung, skin and spleen. Other targets for other antiviral drugs of course will be the primary sites of replication or latency for the particular virus concerned, e.g., liver for hepatitis and peripheral nerves for HSV. Similarly, target tissues for tumors will in fact be the tumors themselves. These tissues are all well-known to the artisan and would not require undue experimentation to select. When screening for antiviral compounds, target tissue can be infected by the virus.
  • Non-target tissues or cells also are screened as part of the method herein. Any number or identity of such tissues or cells can be employed in this regard. In general, tissues for which the parent drug is expected to be toxic will be used as non-target tissues. The selection of a non-target tissue is entirely dependent upon the nature of the prodrug and the activity of the parent. For example, non-hepatic tissues would be selected for prodrugs against hepatitis, and untransformed cells of the same tissue as the tumor will suffice for the antitumor-selective prodrug screen.
  • It should be noted that the method of this invention is distinct from studies typically undertaken to determine oral bioavailability of prodrugs. In oral bioavailability studies, the objective is to identify a prodrug which passes into the systemic circulation substantially converted to parent drug. In the present invention, the objective is to find prodrugs that are not metabolized in the gastrointestinal tract or circulation. Thus, target tissues to be evaluated in the method of this invention generally do not include the small intestines or, if the intestines are included, then the tissues also include additional tissues other than the small intestines.
  • The target and non-target tissues used in the screening method of this invention typically will be in an intact living animal. Prodrugs containing esters are more desirably tested in dogs, monkeys or other animals than rodents; mice and rat plasma contains high circulating levels of esterases that may produce a misleading result if the desired therapeutic subject is a human or higher mammal.
  • It is not necessary to practice this method with intact animals. It also is within the scope of this invention to employ perfused organs, in vitro culture of organs (e.g. skin grafts) or cell lines maintained in various forms of cell culture, e.g. roller bottles or zero gravity suspension systems. For example, MT-2 cells can be used as a target tissue for selecting HIV prodrugs. Thus, the term “tissue” shall not be construed to require organized cellular structures, or the structures of tissues as they may be found in nature, although such would be preferred. Rather, the term “tissue” shall be construed to be synonymous with cells of a particular source, origin or differentiation stage.
  • The target and non-target tissue may in fact be the same tissue, but the tissues will be in different biological status. For example, the method herein could be used to select for prodrugs that confer activity in virally-infected tissue (target tissue) but which remain substantially inactive in virally-uninfected cells (corresponding non-target tissue). The same strategy would be employed to select prophylactic prodrugs, i.e., prodrugs metabolized to antivirally active forms incidental to viral infection but which remain substantially unmetabolized in uninfected cells. Similarly, prodrugs could be screened in transformed cells and the untransformed counterpart tissue. This would be particularly useful in comparative testing to select prodrugs for the treatment of hematological malignancies, e.g. leukemias.
  • Without being limited by any particular theory of operation, tissue selective prodrugs are thought to be selectively taken up by target cells and/or selectively metabolized within the cell, as compared to other tissues or cells. The unique advantage of the methoxyphosphonate prodrugs herein is that their metabolism to the dianion at physiological pH ensures that they will be unable to diffuse back out of the cell. They therefore remain effective for lengthy periods of time and are maintained at elevated intracellular concentrations, thereby exhibiting increased potency. The mechanisms for enhanced activity in the target tissue are believed to include enhanced uptake by the target cells, enhanced intracellular retention, or both mechanisms working together. However, the manner in which selectivity or enhanced delivery occurs in the target tissue is not important. It also is not important that all of the metabolic conversion of the prodrug to the parent compound occurs within the target tissue. Only the final drug activity-conferring conversion need occur in the target tissue; metabolism in other tissues may provide intermediates finally converted to antiviral forms in the target tissue.
  • The degree of selectivity or enhanced delivery that is desired will vary with the parent compound and the manner in which it is measured (% dose distribution or parent drug concentration). In general, if the parent drug already possess a generous therapeutic window, a low degree of selectivity may be sufficient for the desired prodrug. On the other hand, toxic compounds may require more extensive screening to identify selective prodrugs. The relative expense of the method of this invention can be reduced by screening only in the target tissue and tissues against which the parent compound is known to be relatively toxic, e.g. for PMEA, which is nephrotoxic at higher doses, the primary focus will be on kidney and lymphoid tissues.
  • The step of determining the relative antiviral activity of a prodrug in the selected tissues ordinarily is accomplished by assaying target and non-target tissues for the relative presence or activity of a metabolite of the prodrug, which metabolite is known to have, or is converted to, a metabolite having antiviral or antitumor activity. Thus, typically one would determine the relative amount of the parent drug in the tissues over substantially the same time course in order to identify prodrugs that are preferentially metabolized in the target tissue to an antivirally or antitumor active metabolite or precursor thereof which in the target tissue ultimately produces the active metabolite. In the case of antiviral compounds, the active metabolite is the diphosphate of the phosphonate parent compounds. It is this metabolite that is incorporated into the viral nucleic acid, thereby truncating the elongating nucleic acid strand and halting viral replication. Metabolites of the prodrug can be anabolic metabolites, catabolic metabolites, or the product of anabolism and catabolism together. The manner in which the metabolite is produced is not important in the practice of the method of this invention.
  • The method of this invention is not limited to assaying a metabolite which per se possesses antiviral or antitumor activity. Instead, one can assay inactive precursors of the active metabolites. Precursors of the antivirally active diphosphate metabolite include the monophosphate of the parent drug, monophosphates of other metabolites of the parent drug (e.g., an intermediate modification of a substituent on the heterocyclic base), the parent itself and metabolites generated by the cell in converting the prodrug to the parent prior to phosphorylation. The precursor structures may vary considerably as they are the result of cellular metabolism. However, this information is already known or could be readily determined by one skilled in the art.
  • If the prodrug being assayed does not exhibit antitumor or antiviral activity per se then adjustments to the raw assay results may be required. For example, if the intracellular processing of the inactive metabolite to an active metabolite occurs at different rates among the tissues being tested, the raw assay results with the inactive metabolite would need to be adjusted to take account of the differences among the cell types because the relevant parameter is the generation of activity in the target tissue, not accumulation of inactive metabolites. However, determining the proper adjustments would be within the ordinary skill. Thus, when step (d) of the method herein calls for determining the activity, activity can be either measured directly or extrapolated. It does not mean that the method herein is limited to only assaying intermediates that are active per se. For instance, the absence or decline of the prodrug in the test tissues also could be assayed. Step (d) only requires assessment of the activity conferred by the prodrug as it interacts with the tissue concerned, and this may be based on extrapolation or other indirect measurement.
  • Step (d) of the method of this invention calls for determining the “relative” activity of the prodrug. It will be understood that this does not require that each and every assay or series of assays necessarily must also contain runs with the selected non-target tissue. On the contrary, it is within the scope of this invention to employ historical controls of the non-target tissue or tissues, or algorithms representing results to be expected from such non-target tissues, in order to provide the benchmark non-target activity.
  • The results obtained in step (d) are then used optimally to select or identify a prodrug which produces greater antiviral activity in the target tissue than in the non-target tissue. It is this prodrug that is selected for further development.
  • It will be appreciated that some preassessment of prodrug candidates can be undertaken before the practice of the method of this invention. For example, the prodrug will need to be capable of passing largely unmetabolized through the gastrointestinal tract, it will need to be substantially stable in blood, and it should be able to permeate cells at least to some degree. In most cases it also will need to complete a first pass of the hepatic circulation without substantial metabolism. Such prestudies are optional, and are well-known to those skilled in the art.
  • The same reasoning as is described above for antiviral activity is applicable to antitumor prodrugs of methoxyphosphonate nucleotide analogues as well. These include, for example, prodrugs of PMEG, the guanyl analogue of PMEA. In this case, cytotoxic phosphonates such as PMEG are worthwhile candidates to pursue as their cytotoxicity in fact confers their antitumor activity.
  • A compound identified by this novel screening method then can be entered into a traditional preclinical or clinical program to confirm that the desired objectives have been met. Typically, a prodrug is considered to be selective if the activity or concentration of parent drug in the target tissue (% dose distribution) is greater than 2×, and preferably 5×, that of the parent compound in non-target tissue. Alternatively, a prodrug candidate can be compared against a benchmark prodrug. In this case, selectivity is relative rather than absolute. Selective prodrugs will be those resulting in greater than about 10× concentration or activity in the target tissue as compared with the prototype, although the degree of selectivity is a matter of discretion.
  • 5.2 Novel Method for Preparation of Starting Materials or Intermediates
  • Also included herein is an improved method for manufacture of preferred starting materials (parent drugs) of this invention, PMEA and (R)-PMPA. Typically, this method comprises reacting 9-(2-hydroxypropyl)adenine (HPA) or 9-(2-hydroxyethyl)adenine (HEA) with a magnesium alkoxide, thereafter adding the protected aglycon synthon p-toluene-sulfonyloxymethylphosphonate (tosylate) to the reaction mixture, and recovering PMPA or PMEA, respectively.
  • Preferably, HPA is the enriched or isolated R enantiomer. If a chiral HPA mixture is used, R-PMPA can be isolated from the chiral PMPA mixture after the synthesis is completed.
  • Typically the tosylate is protected by lower alkyl groups, but other suitable groups will be apparent to the artisan. It may be convenient to employ the tosylate presubstituted with the prodrug phosphonate substituents which are capable of acting as protecting groups in the tosylation reaction, thereby allowing one to bypass the deprotection step and directly recover prodrug or an intermediate therefore.
  • The alkyl group of the magnesium alkoxide is not critical and can be any C1-C6 branched or normal alkyl, but is preferably t-butyl (for PMPA) or isopropyl (for PMEA). The reaction conditions also are not critical, but preferably comprise heating the reaction mixture at about 70-75° C. with stirring or other moderate agitation.
  • If there is no interest in retaining the phosphonate substituents, the product is deprotected (usually with bromotrimethylsilane where the tosylate protecting group is alkyl), and the product then recovered by crystallization or other conventional method as will be apparent to the artisan.
  • 5.3 Heterocyclic Base
  • In the compounds of this invention depicted in structures (3) and (4), the heterocyclic base B is selected from the structures
    Figure US20050124583A1-20050609-C00012
      • wherein
      • R15 is H, OH, F, Cl, Br, I, OR16, SH, SR16, NH2, or NHR17;
      • R16 is C1-C6 alkyl or C2-C6 alkenyl including —CH3, —CH2CH3, —CH2C≡CH, —CH2CH═CH2 and —C3H7;
      • R17 is C1-C6 alkyl or C2-C6 alkenyl including —CH3, —CH2CH3, —CH2C≡CH, —CH2CH═CH2, and —C3H7;
      • R18 is N, CF, CC1, CBr, CI, CR19, CSR19, or COR19;
      • R19 is H, C1-C9 alkyl, C2-C9 alkenyl, C2-C9 alkynyl, C1-C9 alkyl-C1-C9 alkoxy, or C7-C9 aryl-alkyl unsubstituted or substituted by OH, F, Cl, Br or I, R19 therefore including —CH3, —CH2CH3, —CHCH2, —CHCHBr, —CH2CH2Cl,
      • —CH2CH2F, —CH2CCH, —CH2CHCH2, —C3H7, —CH2OH, —CH2OCH3, —CH2OC2H5, —CH2OCCH, —CH2OCH2CHCH2, —CH2C3H7, —CH2CH2OH, —CH2CH2OCH3,
      • —CH2CH2OC2H5, —CH2CH2OCCH, —CH2CH2OCH2CHCH2, and
      • —CH2CH2OC3H7;
      • R20 is N or CH;
      • R21 is N, CH, CCN, CCF3, CC≡CH or CC(O)NH2;
      • R22 is H, OH, NH2, SH, SCH3, SCH2CH3, SCH2C≡CH, SCH2CH═CH2, SC3H7, NH(CH3), N(CH3)2, NH(CH2CH3), N(CH2CH3)2, NH(CH2C≡CH), NH(CH2CHCH2), NH(C3H7), halogen (F, Cl, Br or I) or X wherein X is —(CH2)m(O)n(CH2)mN(R10)2 wherein each m is independently 0-2, n is 0-1, and
      • R10 independently is H,
      • C1-C15 alkyl, C2-C15 alkenyl, C6-C15 arylalkenyl, C6-C15 arylalkynyl, C2-C15 alkynyl, C1-C6-alkylamino-C1-C6 alkyl, C5-C15 aralkyl, C6-C15 heteroaralkyl, C5-C6 aryl, C2-C6 heterocycloalkyl,
      • C2-C15 alkyl, C3-C15 alkenyl, C6-C15 arylalkenyl, C3-C15 alkynyl, C7-C15 arylalkynyl, C1-C6-alkylamino-C1-C6 alkyl, C5-C15 aralkyl, C6-C15 heteroalkyl or C3-C6 heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N6 has been replaced by —O—,
      • optionally both R10 are joined together with N to form a saturated or unsaturated C2-C5 heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,
      • or one of the foregoing R10 groups which is substituted with 1 to 3 halo, CN or N3; but optionally at least one R10 group is not H;
      • R23 is H, OH, F, Cl, Br, I, SCH3, SCH2CH3, SCH2C≡CH, SCH2CHCH2, SC3H7, OR16, NH2, NHR17 or R22; and
      • R24 is O, S or Se.
  • B also includes both protected and unprotected heterocyclic bases, particularly purine and pyrimidine bases. Protecting groups for exocyclic amines and other labile groups are known (Greene et al. “Protective Groups in Organic Synthesis”) and include N-benzoyl, isobutyryl, 4,4′-dimethoxytrityl (DMT) and the like. The selection of protecting group will be apparent to the ordinary artisan and will depend upon the nature of the labile group and the chemistry which the protecting group is expected to encounter, e.g. acidic, basic, oxidative, reductive or other conditions. Exemplary protected species are N4-benzoylcytosine, N6-benzoyladenine, N2-isobutyrylguanine and the like.
  • Protected bases have the formulas Xa.1, XIa.1, XIb.1, XIIa.1 or XIIIa.1
    Figure US20050124583A1-20050609-C00013
      • wherein R18, R20, R21, R24 have the meanings previously defined; R22A is R39 or R22 provided that R22 is not NH2; R23A is R39 or R23 provided that R23 is not NH2; R39 is NHR40, NHC(O)R36 or CR41N(R38)2 wherein R36 is C1-C19 alkyl, C1-C19 alkenyl, C3-C10 aryl, adamantoyl, alkylanyl, or C3-C10 aryl substituted with 1 or 2 atoms or groups selected from halogen, methyl, ethyl, methoxy, ethoxy, hydroxy and cyano; R38 is C1-C10 alkyl, or both R38 together are 1-morpholino, 1-piperidine or 1-pyrrolidine; R40 is C1-C10 alkyl, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and decanyl; and R41 is hydrogen or CH3.
  • For bases of structures XIa.1 and XIb.1, if R39 is present at R22A or R23A, both R39 groups on the same base will generally be the same. Exemplary R36 are phenyl, phenyl substituted with one of the foregoing R36 aryl substituents, —C10H15 (where C10H15 is 2-adamantoyl), —CH2—C6H5, —C6H5, —CH(CH3)2, —CH2CH3, methyl, butyl, t-butyl, heptanyl, nonanyl, undecanyl, or undecenyl.
  • Specific bases include hypoxanthine, guanine, adenine, cytosine, inosine, thymine, uracil, xanthine, 8-aza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza-8-aza derivatives of adenine, guanine, 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 1-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 3-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 6-azacytosine; 5-fluorocytosine; 5-chlorocytosine; 5-iodocytosine; 5-bromocytosine; 5-methylcytosine; 5-bromovinyluracil; 5-fluorouracil; 5-chlorouracil; 5-iodouracil; 5-bromouracil; 5-trifluoromethyluracil; 5-methoxymethyluracil; 5-ethynyluracil and 5-propynyluracil.
  • Preferably, B is a 9-purinyl residue selected from guanyl, 3-deazaguanyl, 1-deazaguanyl, 8-azaguanyl, 7-deazaguanyl, adenyl, 3-deazaadenyl, 1-dezazadenyl, 8-azaadenyl, 7-deazaadenyl, 2,6-diaminopurinyl, 2-aminopurinyl, 6-chloro-2-aminopurinyl and 6-thio-2-aminopurinyl, or a B′ is a 1-pyrimidinyl residue selected from cytosinyl, 5-halocytosinyl, and 5-(C1-C3-alkyl)cytosinyl.
  • Preferred B groups have the formula
    Figure US20050124583A1-20050609-C00014
      • wherein
      • R22 independently is halo, oxygen, NH2, X or H, but optionally at least one R22 is X;
      • X is —(CH2)m(O)n(CH2)mN(R10)2 wherein m is 0-2, n is 0-1, and
      • R10 independently is H,
      • C1-C15 alkyl, C2-C15 alkenyl, C6-C15 arylalkenyl, C6-C15 arylalkynyl, C2-C15 alkynyl, C1-C6-alkylamino-C1-C6 alkyl, C5-C15 aralkyl, C6-C15 heteroaralkyl, C5-C6 aryl, C2-C6 heterocycloalkyl,
      • C2-C15 alkyl, C3-C15 alkenyl, C6-C15 arylalkenyl, C3-C15 alkynyl, C7-C15 arylalkynyl, C1-C6-alkylamino-C1-C6 alkyl, C5-C15 aralkyl, C6-C15 heteroalkyl or C3-C6 heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N6 has been replaced by —O—,
      • optionally both R10 are joined together with N to form a saturated or unsaturated C2-C5 heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,
      • or one of the foregoing R10 groups is substituted with 1 to 3 halo, CN or N3; but optionally at least one R10 group is not H; and
      • Z is N or CH, provided that the heterocyclic nucleus varies from purine by no more than one Z.
  • E groups represent the aglycons employed in the methoxyphosphonate nucleotide analogues. Preferably, the E group is —CH(CH3)CH2— or —CH2CH2—. Also, it is preferred that the side groups at chiral centers in the aglycon be substantially solely in the (R) configuration (except for hydroxymethyl, which is the enriched (S) enantiomer).
  • R1 is an in vivo hydrolyzable oxyester having the structure —OR35 or —OR6 wherein R35 is defined in column 64, line 49 of U.S. Pat. No. 5,798,340, herein incorporated by reference, and R6 is defined above. Preferably R1 is aryloxy, ordinarily unsubstituted or para-substituted (as defined in R6) phenoxy.
  • R2 is an amino acid residue, optionally provided that any carboxy group linked by less than about 5 atoms to the amidate N is esterified. R2 typically has the structure
    Figure US20050124583A1-20050609-C00015
      • wherein
      • n is 1 or 2;
      • R11 is R6 or H; preferably R6═C3-C9 alkyl; C3-C9 alkyl substituted independently with OH, halogen, O or N; C3-C6 aryl; C3-C6 aryl which is independently substituted with OH, halogen, O or N; or C3-C6 arylalkyl which is independently substituted with OH, halogen, O or N;
      • R12 independently is H or C1-C9 alkyl which is unsubstituted or substituted by substituents independently selected from the group consisting of OH, O, N, COOR11 and halogen; C3-C6 aryl which is unsubstituted or substituted by substituents independently selected from the group consisting of OH, O, N, COOR11 and halogen; or C3-C9 aryl-alkyl which is unsubstituted or substituted by substituents independently selected from the group consisting of OH, O, N, COOR11 and halogen;
      • R13 independently is C(O)—OR11; amino; amide; guanidinyl; imidazolyl; indolyl; sulfoxide; phosphoryl; C1-C3 alkylamino; C1-C3 alkyldiamino; C1-C6 alkenylamino; hydroxy; thiol; C1-C3 alkoxy; C1-C3 alkthiol; (CH2), COOR11; C1-C6 alkyl which is unsubstituted or substituted with OH, halogen, SH, NH2, phenyl, hydroxyphenyl or C7-C10 alkoxyphenyl; C2-C6 alkenyl which is unsubstituted or substituted with OH, halogen, SH, NH2, phenyl, hydroxyphenyl or C7-C10 alkoxyphenyl; and C6-C12 aryl which is unsubstituted or substituted with OH, halogen, SH, NH2, phenyl, hydroxyphenyl or C7-C10 alkoxyphenyl; and
      • R14 is H or C1-C9 alkyl or C1-C9 alkyl independently substituted with OH, halogen, COOR11, O or N; C3-C6 aryl; C3-C6 aryl which is independently substituted with OH, halogen, COOR11, O or N; or C3-C6 arylalkyl which is independently substituted with OH, halogen, COOR11, O or N.
  • Preferably, R11 is C1-C6 alkyl, most preferably isopropyl, R13 is the side chain of a naturally occurring amino acid, n=1, R12 is H and R14 is H. In the compound of structure (2), the invention includes metabolites in which the phenoxy and isopropyl esters have been hydrolyzed to —OH. Similarly, the de-esterified enriched phosphonoamidate metabolites of compounds (5a), 5(b) and (6) are included within the scope of this invention.
  • Aryl and “0” or “N” substitution are defined in column 16, lines 42-58, of U.S. Pat. No. 5,798,340.
  • Typically, the amino acids are in the natural or l amino acids. Suitable specific examples are set forth in U.S. Pat. No. 5,798,340, for instance Table 4 and col. 8-10 therein.
  • Alkyl as used herein, unless stated to the contrary, is a normal, secondary, tertiary or cyclic hydrocarbon. Unless stated to the contrary alkyl is C1-C12. Examples are —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3), —CH2CH(CH3)2, —CH(CH3)CH2CH3, —C(CH3)3, —CH2CH2CH2CH2CH3, —CH(CH3)CH2CH2CH3, —CH(CH2CH3)2, —C(CH3)2CH2CH3), —CH(CH3)CH(CH3)2, —CH2CH2CH(CH3)2), —CH2CH(CH3)CH2CH3, —CH2CH2CH2CH2CH2CH3, —CH(CH3)CH2CH2CH2CH3, —CH(CH2CH3)(CH2CH2CH3), —C(CH3)2CH2CH2CH3, —CH(CH3)CH(CH3)CH2CH3, —CH(CH3)CH2CH(CH3)2, —C(CH3)(CH2CH3)2, —CH(CH2CH3)CH(CH3)2, —C(CH3)2CH(CH3)2, and —CH(CH3)C(CH3)3. Alkenyl and alkynyl are defined in the same fashion, but contain at least one double or triple bond, respectively.
  • Where enol or keto groups are disclosed, the corresponding tautomers are to be construed as taught as well.
  • The prodrug compounds of this invention are provided in the form of free base or the various salts enumerated in U.S. Pat. No. 5,798,340, and are formulated with pharmaceutically acceptable excipients or solvating diluents for use as pharmaceutical products also as set forth in U.S. Pat. No. 5,798,340. These prodrugs have the antiviral and utilities already established for the parent drugs (see U.S. Pat. No. 5,798,340 and other citations relating to the methoxyphosphonate nucleotide analogues). It will be understood that the diastereomer of structure (4) at least is useful as an intermediate in the chemical production of the parent drug by hydrolysis in vitro, regardless of its relatively unselective character as revealed in the studies herein.
  • 6. EXAMPLES
  • The invention will be more fully understood by reference to the following examples:
  • Example 1a
  • Figure US20050124583A1-20050609-C00016
  • Adenine to PMEA using Magnesium Isopropoxide. To a suspension of adenine (16.8 g, 0.124 mol) in DMF (41.9 ml) was added ethylene carbonate (12.1 g, 0.137 mol) and sodium hydroxide (0.100 g, 0.0025 mol). The mixture was heated at 130° C. overnight. The reaction was cooled to below 50° C. and toluene (62.1 ml) was added. The slurry was further cooled to 5° C. for 2 hours, filtered, and rinsed with toluene (2×). The wet solid was dried in vacuo at 65° C. to yield 20.0 g (90%) of 9-(2-hydroxyethyl)adenine as an off-white solid. Mp: 238-240° C.
    Figure US20050124583A1-20050609-C00017
  • 9-(2-Hydroxyethyl)adenine (HEA) (20.0 g, 0.112 mol) was suspended in DMF (125 ml) and heated to 80° C. Magnesium isopropoxide (11.2 g, 0.0784 mol), or alternatively magnesium t-butoxide, was added to the mixture followed by diethyl p-toluenesulfonyloxymethylphosphonate (66.0 g, 0.162 mol) over one hour. The mixture was stirred at 80° C. for 7 hours. 30 ml of volatiles were removed via vacuum distillation and the reaction was recharged with 30 ml of fresh DMF. After cooling to room temperature, bromotrimethylsilane (69.6 g, 0.450 mol) was added and the mixture heated to 80° C. for 6 hours. The reaction was concentrated to yield a thick gum. The gum was dissolved into 360 ml water, extracted with 120 ml dichloromethane, adjusted to pH 3.2 with sodium hydroxide, and the resulting slurry stirred at room temperature overnight. The slurry was cooled to 4° C. for one hour. The solids were isolated by filtration, washed with water (2×), and dried in vacuo at 56° C. to yield 20 g (65.4%) of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as a white solid. Mp: >200° C. dec. 1H NMR (D2O) δ 3.49 (t, 2H); 3.94 (t, 2H); 4.39 (t, 2H); 8.13 (s, 1H); 8.22 (s, 1H).
  • Example 1b
  • Figure US20050124583A1-20050609-C00018
  • Adenine to PMPA using Magnesium t-Butoxide. To a suspension of adenine (40 g, 0.296 mol) in DMF (41.9 ml) was added (R)-propylene carbonate (34.5 g, 0.338 mol) and sodium hydroxide (0.480 g, 0.012 mol). The mixture was heated at 130° C. overnight. The reaction was cooled to 100° C. and toluene (138 ml) was added followed by methanesulfonic acid (4.7 g, 0.049 mol) while maintaining the reaction temperature between 100-110° C. Additional toluene (114 ml) was added to create a homogeneous solution. The solution was cooled to 3° C. over 7 hours and then held at 3° C. for one hour. The resulting solid was isolated by filtration and rinsed with acetone (2×). The wet solid was dried in vacuo at 80° C. to yield 42.6 g (75%) of (R)-9-[2-(hydroxy)propyl]adenine (HPA) as an off-white solid. Mp: 188-190° C.
    Figure US20050124583A1-20050609-C00019
  • (R)-9-[2-(hydroxy)propyl]adenine (HPA) (20.0 g, 0.104 mol) was suspended in DMF (44.5 ml) and heated to 65° C. Magnesium t-butoxide (14.2 g, 0.083 mol), or alternatively magnesium isopropoxide, was added to the mixture over one hour followed by diethyl p-toluenesulfonyloxymethylphosphonate (66.0 g, 0.205 mol) over two hours while the temperature was kept at 78° C. The mixture was stirred at 75° C. for 4 hours. After cooling to below 50° C., bromotrimethylsilane (73.9 g, 0.478 mol) was added and the mixture heated to 77° C. for 3 hours. When complete, the reaction was heated to 80° C. and volatiles were removed via atmospheric distillation. The residue was dissolved into water (120 ml) at 50° C. and then extracted with ethyl acetate (101 ml). The pH of the aqueous phase was adjusted to pH 1.1 with sodium hydroxide, seeded with authentic (R)-PMPA, and the pH of the aqueous layer was readjusted to pH 2.1 with sodium hydroxide. The resulting slurry was stirred at room temperature overnight. The slurry was cooled to 4° C. for three hours. The solid was isolated by filtration, washed with water (60 ml), and dried in vacuo at 50° C. to yield 18.9 g (63.5%) of crude(R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA) as an off-white solid.
  • The crude(R)-9-[2-(phosphonomethoxy)propyl]adenine was heated at reflux in water (255 ml) until all solids dissolved. The solution was cooled to room temperature over 4 hours. The resulting slurry was cooled at 4° C. for three hours. The solid was isolated by filtration, washed with water (56 ml) and acetone (56 ml), and dried in vacuo at 50° C. to yield 15.0 g (50.4%) of (R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA) as a white solid. Mp: 278-280° C.
  • Example 2 Preparation of GS-7171 (III)
  • Figure US20050124583A1-20050609-C00020
    Figure US20050124583A1-20050609-C00021
  • A glass-lined reactor was charged with anhydrous PMPA, (I) (14.6 kg, 50.8 mol), phenyl (9.6 kg, 102 mol), and 1-methyl-2-pyrrolidinone (39 kg). The mixture was heated to 85° C. and triethylamine (6.3 kg, 62.3 mol) added. A solution of 1,3-dicyclohexylcarbodiimide (17.1 kg, 82.9 mol) in 1-methyl-2-pyrrolidinone (1.6 kg) was then added over 6 hours at 100° C. Heating was continued for 16 hours. The reaction was cooled to 45° C., water (29 kg) added, and cooled to 25° C. Solids were removed from the reaction by filtration and rinsed with water (15.3 kg). The combined filtrate and rinse was concentrated to a tan slurry under reduced pressure, water (24.6 kg) added, and adjusted to pH=11 with NaOH (25% in water). Fines were removed by filtration through diatomaceous earth (2 kg) followed by a water (4.4 kg) rinse. The combined filtrate and rinse was extracted with ethyl acetate (28 kg). The aqueous solution was adjusted to pH=3.1 with HCl (37% in water) (4 kg). Crude II was isolated by filtration and washed with methanol (12.7 kg). The crude II wet cake was slurried in methanol (58 kg). Solids were isolated by filtration, washed with methanol (8.5 kg), and dried under reduced pressure to yield 9.33 kg II as a white powder: 1H NMR (D2O) δ 1.2 (d, 3H), 3.45 (q, 2H), 3.7 (q, 2H), 4 (m, 2H), 4.2 (q, 2H), 4.35 (dd, 2H), 6.6 (d, 2H), 7 (t, 1H), 7.15 (t, 2H), 8.15 (s, 1H), 8.2 (s, 1H); 31P NMR (D2O) δ 15.0 (decoupled).
  • GS-7171 (III). (Scheme 1) A glass-lined reactor was charged with monophenyl PMPA, (II), (9.12 kg, 25.1 mol) and acetonitrile (30.7 kg). Thionyl chloride (6.57 kg, 56.7 mol) was added below 50° C. The mixture was heated at 75° C. until solids dissolved. Reaction temperature was increased to 80° C. and volatiles (11.4 kg) collected by atmospheric distillation under nitrogen. The pot residue was cooled to 25° C., dichloromethane (41 kg) added, and cooled to −29° C. A solution of (L)-alanine isopropyl ester (7.1 kg, 54.4 mol) in dichloromethane (36 kg) was added over 60 minutes at −18° C. followed by triethylamine (7.66 kg, 75.7 mol) over 30 minutes at −18 to −11° C. The reaction mixture was warmed to room temperature and washed five times with sodium dihydrogenphosphate solution (10% in water, 15.7 kg each wash). The organic solution was dried with anhydrous sodium sulfate (18.2 kg), filtered, rinsed with dichloromethane (28 kg), and concentrated to an oil under reduced pressure. Acetone (20 kg) was charged to the oil and the mixture concentrated under reduced pressure. Acetone (18.8 kg) was charged to the resulting oil. Half the product solution was purified by chromatography over a 38×38 cm bed of 22 kg silica gel 60, 230 to 400 mesh. The column was eluted with 480 kg acetone. The purification was repeated on the second half of the oil using fresh silica gel and acetone. Clean product bearing fractions were concentrated under reduced pressure to an oil. Acetonitrile (19.6 kg) was charged to the oil and the mixture concentrated under reduced pressure. Acetonitrile (66.4 kg) was charged and the solution chilled to 0 to −5° C. for 16 hours. Solids were removed by filtration and the filtrate concentrated under reduced pressure to 5.6 kg III as a dark oil: 1H NMR (CDCl3) δ 1.1 (m 12H), 3.7 (m, 1H), 4.0 (m, 5H), 4.2 (m, 1H), 5.0 (m, 1H), 6.2 (s, 2H), 7.05 (m, 5H), 8.0 (s, 1H), 8.25 (d, 1H); 31P NMR (CDCl3) δ 21.0, 22.5 (decoupled).
  • Alternate Method for GS-7171(III)
  • Figure US20050124583A1-20050609-C00022
  • Monophenyl PMPA (II). A round-bottom flask with reflux condenser and nitrogen inlet was placed in a 70° C. oil bath. The flask was charged with anhydrous PMPA (I) (19.2 g, 67 mmol), N,N-dimethylformamide (0.29 g, 3.3 mmol), and tetramethylene sulfone (40 mL). Thionyl chloride (14.2 g, 119 mmol) was added over 4 hours. Heating was increased to 100° C. over the same time. A homogeneous solution resulted. Phenoxytrimethylsilane (11.7 g, 70 mmol) was added to the solution over 5 minutes. Heating in the 100° C. oil bath continued for two hours more. The reaction was poured into rapidly stirring acetone (400 mL) with cooling at 0° C. Solids were isolated by filtration, dried under reduced pressure, and dissolved in methanol (75 mL). The solution pH was adjusted to 3.0 with potassium hydroxide solution (45% aq.) with cooling in ice/water. The resulting solids were isolated by filtration, rinsed with methanol, and dried under reduced pressure to 20.4 g II (Scheme 2) as a white powder.
  • GS-7171 (III). Monophenyl PMPA (II) (3 g, 8.3 mmol), tetramethylene sulfone (5 mL), and N,N-dimethylformamide (1 drop) were combined in a round bottom flask in a 40° C. oil bath. Thionyl chloride (1.96 g, 16.5 mmol) was added. After 20 minutes the clear solution was removed from heat, diluted with dichloromethane (10 ml), and added to a solution of (L)-alanine isopropyl ester (5 g, 33 mmol) and diisopropylethylamine (5.33 g, 41 mmol) in dichloromethane (20 mL) at −10° C. The reaction mixture was warmed to room temperature and washed three times with sodium dihydrogenphosphate solution (10% aq., 10 mL each wash). The organic solution was dried over anhydrous sodium sulfate and concentrated under reduced pressure to a oil. The oil was combined with fumaric acid (0.77 g, 6.6 mmol) and acetonitrile (40 mL) and heated to reflux to give a homogeneous solution. The solution was cooled in an ice bath and solids isolated by filtration. The solid GS-7171 fumarate salt was dried under reduced pressure to 3.7 g. The salt (3.16 g, 5.3 mmol) was suspended in dichloromethane (30 mL) and stirred with potassium carbonate solution (5 mL, 2.5 M in water) until the solid dissolved. The organic layer was isolated, then washed with water (5 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 2.4 g III as a tan foam.
  • Example 3 Diastereomer Separation by Batch Elution Chromatography
  • The diastereomers of GS-7171 (III) were resolved by batch elution chromatography using a commercially available Chiralpak AS, 20 μm, 21×250 mm semi-preparative HPLC column with a Chiralpak AS, 20 μm, 21×50 mm guard column. Chiralpak® AS is a proprietary packing material manufactured by Diacel and sold in North America by Chiral Technologies, Inc. (U.S. Pat. Nos. 5,202,433, RE 35,919, 5,434,298, 5,434,299 and 5,498,752). Chiralpak AS is a chiral stationary phase (CSP) comprised of amylosetris[(S)-α-methylbenzyl carbamate] coated onto a silica gel support.
  • The GS-7171 diastereomeric mixture was dissolved in mobile phase, and approximately 1 g aliquots of GS-7171 were pumped onto the chromatographic system. The undesired diastereomer, designated GS-7339, was the first major broad (approx. 15 min. duration) peak to elute from the column. When the GS-7339 peak had finished eluting, the mobile phase was immediately switched to 100% methyl alcohol, which caused the desired diastereomer, designated GS-7340 (IV), to elute as a sharp peak from the column with the methyl alcohol solvent front. The methyl alcohol was used to reduce the over-all cycle time. After the first couple of injections, both diastereomers were collected as a single large fractions containing one of the purified diastereomers (>99.0% single diastereomer). The mobile phase solvents were removed in vacuo to yield the purified diastereomer as a friable foam.
  • About 95% of the starting GS-7171 mass was recovered in the two diastereomer fractions. The GS-7340 fraction comprised about 50% of the total recovered mass.
  • The chromatographic conditions were as follows:
    Mobile Phase (Initial) GS-7171 - Acetonitrile:Isopropyl
    Alcohol (90:10)
    (Final) 100% Methyl Alcohol
    Flow 10 mL/minute
    Run Time About 45 minute
    Detection UV at 275 nm
    Temperature Ambient
    Elution Profile GS-7339 (diastereomer B)
    GS-7340 (diastereomer A; (IV))

    Diastereomer Separation of GS-7171 by SMB Chromatography
  • For a general description of simulated moving bed (SMB) chromatography, see Strube et al., “Organic Process Research and Development” 2:305-319 (1998).
  • GS-7340 (IV). GS-7171 (III), 2.8 kg, was purified by simulated moving bed chromatography over 10 cm by 5 cm beds of packing (Chiral Technologies Inc., 20 micron Chiralpak AS coated on silica gel) (1.2 kg). The columns were eluted with 30% methanol in acetonitrile. Product bearing fractions were concentrated to a solution of IV in acetonitrile (2.48 kg). The solution solidified to a crystalline mass wet with acetonitrile on standing. The crystalline mass was dried under reduced pressure to a tan crystalline powder, 1.301 kg IV, 98.7% diastereomeric purity: mp 117-120° C.; 1H NMR (CDCl3) δ 1.15 (m 12H), 3.7 (t, 1H), 4.0 (m, 5H), 4.2 (dd, 1H), 5.0 (m, 1H), 6.05 (s, 2H), 7.1 (m, 5H), 8.0 (s, 1H), 8.2 (s, 1H); 31P NMR (CDCl3) δ 21.0 (decoupled).
  • Diastereomer Separation by C18 RP-HPLC
  • GS-7171 (III) was chromatographed by reverse phase HPLC to separate the diastereomers using the following summary protocol.
    Chromatographic Phenomenex Luna ™ C18(2), 5 μm, 100 Å
    column: pore size,
    (Phenomenex, Torrance, CA), or equivalent
    Guard column: Pellicular C18 (Alltech, Deerfield, IL), or equivalent
    Mobile Phase: A - 0.02% (85%) H3PO4 in water:acetonitrile
    (95:5)
    B - 0.02% (85%) H3PO4 in water:acetonitrile
    (50:50)
    Mobile Phase Gradient:
    % Mobile Phase % Mobile Phase
    Time A B
    0 100 0
    5 100 0
    7 70 30
    32 70 30
    40 0 100
    50 0 100
    Run Time: 50 minutes
    Equilibration Delay: 10 min at 100% mobile phase A
    Flow Rate: 1.2 mL/min
    Temperature: Ambient
    Detection: UV at 260 nm
    Sample Solution: 20 mM sodium phosphate buffer, pH 6
    Retention Times: GS-7339, about 25 minutes
    GS-7340, about 27 minutes

    Diastereomer Separation by Crystallization
  • GS-7340 (IV). A solution of GS-7171 (III) in acetonitrile was concentrated to an amber foam (14.9 g) under reduced pressure. The foam was dissolved in acetonitrile (20 mL) and seeded with a crystal of IV. The mixture was stirred overnight, cooled to 5° C., and solids isolated by filtration. The solids were dried to 2.3 g IV as white crystals, 98% diastereomeric purity (31P NMR): 1H NMR (CDCl3) δ 1.15 (m 12H), 3.7 (t, 1H), 3.95 (m, 2H), 4.05 (m, 2H), 4.2 (m, 2H), 5.0 (m, 1H), 6.4 (s, 2H), 7.1 (m, 5H), 8.0 (s, 1H), 8.2 (s, 1H); 31P NMR (CDCl3) δ 19.5 (decoupled). X-ray crystal analysis of a single crystal selected from this product yielded the following data:
    Crystal Color, Habit colorless, column
    Crystal Dimensions 0.25 × 0.12 × 0.08 mm
    Crystal System orthorhombic
    Lattice Type Primitive
    Lattice Parameters a = 8.352(1) Å
    b = 15.574(2) Å
    c = 18.253(2) Å
    V = 2374.2(5) Å3
    Space Group P212121 (#19)
    Z value 4
    Dcalc 1.333 g/cm3
    F000 1008.00
    μ(MoKα) 1.60 cm−1
  • Example 4 Preparation of Fumarate Salt of GS-7340
  • GS-7340-02 (V). (Scheme 1) A glass-lined reactor was charged with GS-7340 (IV), (1.294 kg, 2.71 mol), fumaric acid (284 g, 2.44 mol), and acetonitrile (24.6 kg). The mixture was heated to reflux to dissolve the solids, filtered while hot and cooled to 5° C. for 16 hours. The product was isolated by filtration, rinsed with acetonitrile (9.2 kg), and dried to 1329 g (V) as a white powder: mp 119.7-121.1° C.; [α]D 20 −41.7° (c 1.0, acetic acid).
  • Example 5 Preparation of GS-7120 (VI)
  • Figure US20050124583A1-20050609-C00023
  • A 5 L round bottom flask was charged with monophenyl PMPA, (II), (200 g, 0.55 mol) and acetonitrile (0.629 kg). Thionyl chloride (0.144 kg, 1.21 mol) was added below 27° C. The mixture was heated at 70° C. until solids dissolved. Volatiles (0.45 L) were removed by atmospheric distillation under nitrogen. The pot residue was cooled to 25° C., dichloromethane (1.6 kg) was added and the mixture was cooled to −20° C. A solution of (L)-α aminobutyric acid ethyl ester (0.144 kg, 1.1 mol) in dichloromethane (1.33 kg) was added over 18 minutes at −20 to −10° C. followed by triethylamine (0.17 kg, 1.65 mol) over 15 minutes at −8 to −15° C. The reaction mixture was warmed to room temperature and washed four times with sodium dihydrogenphosphate solution (10% aq., 0.3 L each wash). The organic solution was dried with anhydrous sodium sulfate (0.5 kg) and filtered. The solids were rinsed with dichloromethane (0.6 kg) and the combined filtrate and rinse was concentrated to an oil under reduced pressure. The oil was purified by chromatography over a 15×13 cm bed of 1.2 kg silica gel 60, 230 to 400 mesh. The column was eluted with a gradient of dichloromethane and methanol. Product bearing fractions were concentrated under reduced pressure to afford 211 g VI (Scheme 3) as a tan foam.
  • Example 5a Diastereomer Separation of GS-7120 by Batch Elution Chromatography
  • The diastereomeric mixture was purified using the conditions described for GS-7171 in Example 3A except for the following:
    Mobile Phase (Initial) GS-7120 - Acetonitrile:Isopropyl Alcohol (98:2)
    (Final) 100% Methyl Alcohol
    Elution Profile: GS-7341 (diastereomer B)
    GS-7342 (diastereomer A)
  • Example 6 Diastereomer Separation of GS-7120 by Crystallization
  • A 1 L round bottom flask was charged with monophenyl PMPA, (II), (50 g, 0.137 mol) and acetonitrile (0.2 L). Thionyl chloride (0.036 kg, 0.303 mol) was added with a 10° C. exotherm. The mixture was heated to reflux until solids dissolved. Volatiles (0.1 L) were removed by atmospheric distillation under nitrogen. The pot residue was cooled to 25° C., dichloromethane (0.2 kg) was added, and the mixture was cooled to −20° C. A solution of (L)-α aminobutyric acid ethyl ester (0.036 kg, 0.275 mol) in dichloromethane (0.67 kg) was added over 30 minutes at −20 to −8° C. followed by triethylamine (0.042 kg, 0.41 mol) over 10 minutes at up to −6° C. The reaction mixture was warmed to room temperature and washed four times with sodium dihydrogenphosphate solution (10% aq., 0.075 L each wash). The organic solution was dried with anhydrous sodium sulfate (0.1 kg) and filtered. The solids were rinsed with ethyl acetate (0.25 L, and the combined filtrate and rinse was concentrated to an oil under reduced pressure. The oil was diluted with ethyl acetate (0.25 L), seeded, stirred overnight, and chilled to −15° C. The solids were isolated by filtration and dried under reduced pressure to afford 17.7 g of GS-7342 (Table 5) as a tan powder: 1H NMR (CDCl3) δ 0.95 (t, 3H), 1.3 (m, 6H), 1.7, (m, 2H), 3.7 (m, 2H), 4.1 (m, 6H), 4.4 (dd, 1H), 5.8 (s, 2H), 7.1 (m, 5H), 8.0 (s, 1H), 8.4 (s, 1H); 31P NMR (CDCl3) δ 21 (decoupled).
  • Example 7 Diastereomer Separation of GS-7097
  • The diastereomeric mixture was purified using the conditions described for GS-7171 (Example 3A) except for the following:
    Mobile Phase (Initial) GS-7120 - Acetonitrile:Isopropyl Alcohol (95:5)
    (Final) 100% Methyl Alcohol
    Elution Profile GS-7115 (diastereomer B)
    GS-7114 (diastereomer A)
  • Example 8 Alternative Procedure for Preparation of GS-7097
  • GS-7097: Phenyl PMPA, Ethyl L-Alanyl Amidate. Phenyl PMPA (15.0 g, 41.3 mmol), L-alanine ethyl ester hydrochloride (12.6 g, 83 mmol) and triethylamine (11.5 mL, 83 mmol) were slurried together in 500 mL pyridine under dry N2. This suspension was combined with a solution of triphenylphosphine (37.9 g, 145 mmol), Aldrithiol 2 (2,2′-dipyridyl disulfide) (31.8 g, 145 mmol), and 120 mL pyridine. The mixture was heated at an internal temperature of 57° C. for 15 hours. The complete reaction was concentrated under vacuum to a yellow paste, 100 g. The paste was purified by column chromatography over a 25×11 cm bed of 1.1 kg silica gel 60, 230 to 400 mesh. The column was eluted with 8 liters of 2% methanol in dichloromethane followed by a linear gradient over a course of 26 liters eluent up to a final composition of 13% methanol. Clean product bearing fractions were concentrated to yield 12.4 g crude (5), 65% theory. This material was contaminated with about 15% (weight) triethylamine hydrochloride by 1H NMR. The contamination was removed by dissolving the product in 350 mL ethyl acetate, extracting with 20 mL water, drying the organic solution over anhydrous sodium sulfate, and concentrating to yield 11.1 g pure GS-7097 as a white solid, 58% yield. The process also is employed to synthesize the diastereomeric mixture of GS-7003a and GS-7003b (the phenylalanyl amidate) and the mixture GS-7119 and GS-7335 (the glycyl amidate). These diastereomers are separated using a batch elution procedure such as shown in Example 3A, 6 and 7.
  • Example 9 In Vitro Studies of Prodrug Diastereomers
  • The in vitro anti-HIV-1 activity and cytotoxicity in MT-2 cells and stability in human plasma and MT-2 cell extracts of GS-7340 (freebase) and tenofovir disoproxil fumarate (TDF), are shown in Table 1. GS-7340 shows a 10-fold increase in antiviral activity relative to TDF and a 200-fold increase in plasma stability. This greater plasma stability is expected to result in higher circulating levels of GS-7340 than TDF after oral administration.
    TABLE 1
    In Vitro Activity and Stability
    Stability T ½ (min)
    HIV-1 MT-2
    Activity Cytotoxicity Human Cell
    IC50 μM CC50 μM Plasma Extract (P/MT-2)
    GS 7340 0.005 >40 90.0 28.3 3.2
    TDF 0.05 70 0.41 70.7 0.006
    Tenofovir 5 6000
  • In order to estimate the relative intracellular PMPA resulting from the intracellular metabolism of TDF as compared to that from GS-7340, both prodrugs and PMPA were radiolabeled and spiked into intact human whole blood at equimolar concentrations. After 1 hour, plasma, red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) were isolated and analyzed by HPLC with radiometric detection. The results are shown in Table 2.
  • After 1 hour, GS-7340 results in 10× and 30× the total intracellular concentration of PMPA species in PBMCs as compared to TDF and PMPA, respectively. In plasma after 1 hour, 84% of the radioactivity is due to intact GS-7340, whereas no TDF is detected at 1 hour. Since no intact TDF is detected in plasma, the 10× difference at 1 hour between TDF and GS-7340 is the minimum difference expected in vivo. The HPLC chromatogram for all three compounds in PBMCs is shown in FIG. 1.
    TABLE 2
    PMPA Metabolites in Plasma, PBMCs and RBCs After 1 h
    Incubation of PMPA Prodrugs or PMPA in Human Blood.
    Total Metabolites (% of Total Peak Area)
    C-14
    Recovered, PMPA PMPAp, PMPApp, Met. X, Met. Y, GS 7340,
    Compound Matrix μg-eq % % % % % %
    GS-7340 Plasma/ 43.0 1 2 13 84
    FP
    (60 μg-eq) PBMC 1.25 45 16 21 18
    RBC/FP 12.6 8 24 11 57
    Mono-
    PMPA PMPAp PMPApp POC GS-4331
    GS-4331 Plasma/ 48.1 11 89
    (TDF) FP
    (60 μg-eq) PBMC 0.133 50 25 18 7
    RBC/FP 10.5 93 7.0
    PMPA PMPAp PMPApp
    PMPA Plasma/ 55.7 100
    FP
    (60 μg-eq) PBMC 0.033 86 14
    RBC/FP 3.72 74 10 16
  • Met. X and Met Y (metabolites X and Y) are shown in Table 5. Lower case “p” designates phosphorylation. These results were obtained after 1 hour in human blood. With increasing time, the in vitro differences are expected to increase, since 84% of GS-7340 is still 10 intact in plasma after one hour. Because intact GS-7340 is present in plasma after oral administration, the relative clinical efficacy should be related to the IC50 values seen in vitro.
  • In Table 3 below, IC50 values of tenofovir, TDF, GS-7340, several nucleosides and the protease inhibitor nelfinivir are listed. As shown, nelfinavir and GS-7340 are 2-3 orders of magnitude more potent than all other nucleotides or nucleosides.
    TABLE 3
    In Vitro Anti-HIV-1 Activities of Antiretroviral Compounds
    Compound IC50 (μM)
    Adefovir (PMEA) 13.4 ± 4.21
    Tenofovir (PMPA)  6.3 ± 3.31
    AZT  0.17 ± 0.081
    3TC  1.8 ± 0.251
    d4T   8 ± 2.51
    Nelfinavir  0.006 ± 0.0021
    TDF 0.05 
    GS 7340 0.005

    1A. S. Mulato and J. M. Cherrington, Antiviral Research 36, 91 (1997)
  • Additional studies of the in vitro cell culture anti-HIV-1 activity and CC50 of separated diastereomers of this invention were conducted and the results tabulated below.
    TABLE 4
    Effect of Diastereomer
    Diastereomer Fold A/B CC50
    Compound residue IC50 (μM) change activity (μM)
    PMPA 5  1× 6000
    Ala-methylester Mixture 1:1 0.025 200× 20× 80
    GS-6957a A 0.0075 670×
    GS-6957b 0.15  33×
    Phe-methylester Mixture 1:1 0.03 170× 10× 60
    GS-7003a A 0.01 500×
    GS-7003b B 0.1  50××
    Gly-ethylester Mixture 1:1 0.5  10× 20×
    GS-7119 A 0.05 100× >100
    GS-7335 B 1.0  5×
    Ala-isopropyl Mixture 1:1 0.01 500× 12×
    GS-7340 A 0.005 1,000×   40
    GS-7339 B 0.06  83× >100
    ABA-ethyl Mixture 1:1 0.008 625× 7.5×  >100
    GS-7342 A 0.004 1,250×  
    GS-7341 B 0.03 170×
    Ala-ethyl Mixture 1:1 0.02 250× 10× 60
    GS-7114 A 0.005 1,000×  
    GS-7115 B 0.05   100××
  • Assay reference: Arimilli, M N, et al., (1997) Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antiviral Chemistry and Chemotherapy 8(6):557-564.
  • “Phe-methylester” is the methylphenylalaninyl monoamidate, phenyl monoester of tenofovir; “gly-methylester” is the methylglycyl monoamidate, phenyl monoester of tenofovir.
  • In each instance above, isomer A is believed to have the same absolute stereochemistry as GS-7340 (S), and isomer B is believed to have the same absolute stereochemistry that of GS-7339.
  • The in vitro metabolism and stability of separated diastereomers were determined in PLCE, MT-2 extract and human plasma. A biological sample listed below, 80 μL, was transferred into a screw-capped centrifuge tube and incubated at 37° C. for 5 min. A solution containing 0.2 mg/mL of the test compound in a suitable buffer, 20 μL, was added to the biological sample and mixed. The reaction mixture, 20 mL, was immediately sampled and mixed with 60 μL of methanol containing 0.015 mg/mL of 2-hydroxymethylnaphthalene as an internal standard for HPLC analysis. The sample was taken as the time-zero sample. Then, at specific time points, the reaction mixture, 20 μL, was sampled and mixed with 60 μL of methanol containing the internal standard. The mixture thus obtained was centrifuged at 15,000 G for 5 min and the supernatant was analyzed with HPLC under the conditions described below.
  • The biological samples evaluated are as follows.
  • (1) PLCE (porcine liver carboxyesterase from Sigma, 160 u/mg protein, 21 mg protein/mL) diluted 20 fold with PBS (phosphated-buffered saline).
  • (2) MT-2 cell extract was prepared from MT-2 cells according to the published procedure [A. Pompon, I. Lefebvre, J.-L. Imbach, S. Kahn, and D. Farquhar, “Antiviral Chemistry & Chemotherapy”, 5:91-98 (1994)] except for using HEPES buffer described below as the medium.
  • (3) Human plasma (pooled normal human plasma from George King Biomedical Systems, Inc.)
  • The buffer systems used in the studies are as follows.
  • In the study for PLCE, the test compound was dissolved in PBS. PBS (phosphate-buffered saline, Sigma) contains 0.01 M phosphate, 0.0027 M potassium chloride, and 0.137 M sodium chloride. pH 7.4 at 37° C.
  • In the study for MT-2 cell extracts, the test compound was dissolved in HEPES buffer. HEPES buffer contains 0.010 M HEPES, 0.05 M potassium chloride, 0.005 M magnesium chloride, and 0.005 M dl-dithiothreitol. pH 7.4 at 37° C.
  • In the study for human plasma, the test compound was dissolved in TBS. TBS (tris-buffered saline, Sigma) contains 0.05 M Tris, 0.0027 M potassium chloride, and 0.138 M sodium chloride. pH 7.5 at 37° C.
  • The HPLC analysis was carried out under the following conditions.
    Column: Zorbax Rx-C8, 4.6 × 250 mm, 5μ
    (MAC-MOD Analytical, Inc. Chadds Ford, PA)
    Detection: UV at 260 nm
    Flow Rate: 1.0 mL/min
    Run Time: 30 min
    Injection Volume: 20 μL
    Column Temperature: Ambient temperature
    Mobile Phase A: 50 mM potassium phosphate
    (pH 6.0)/CH3CN = 95/5 (v/v)
    Mobile Phase B: 50 mM Potassium phosphate
    (pH 6.0)/CH3CN = 50/50 (v/v)
    Gradient Run:  0 min 100% Mobile Phase A
    25 min 100% Mobile Phase B
    30 min 100% Mobile Phase B
  • The results are shown below in Table 5 (also including selected IC50 data from Table 4).
    TABLE 5
    In Vitro Metabolism of Isomers A and B of PMPA monoamidate at 37° C.
    Human
    HIV MT-2 extract Plasma
    PMPA monoamidate IC50 PLCE hydrolysis hydrolysis rate Stability
    No. structure (□M) rate and product and product (HP)
    1
    Figure US20050124583A1-20050609-C00024
    0.005 t½ = 2.9 min Met. X & PMPA t½ = 2.9 min Met. X & PMPA t½ = 148 min Met. Y
    2
    Figure US20050124583A1-20050609-C00025
    0.05 t½ = 8.0 min Met. X & PMPA t½ = 150.6 min Met. X & PMPA t½ = 495 min Met. Y
    3
    Figure US20050124583A1-20050609-C00026
    0.005 t½ = 3.3 min Met. X & PMPA t½ = 28.3 min Met. X & PMPA t½ = 90.0 min Met. Y
    4
    Figure US20050124583A1-20050609-C00027
    0.06 t½ = 10.1 min Met. X & PMPA t½ > 1000 min t½ = 231 min Met. Y
    5
    Figure US20050124583A1-20050609-C00028
    0.004 t½ = 3.9 min Met. X t½ = 49.2 min Met. X & PMPA t½ = 103 min Met. Y
    6
    Figure US20050124583A1-20050609-C00029
    0.03 t½ = 11.3 min Met. X t½ > 1000 min t½ = 257 min Met. Y
    7
    Figure US20050124583A1-20050609-C00030
    0.05 t½ < 0.14 min MonoPOC PMPA t½ = 70.7 min monoPOC PMPA t½ = 0.41 min monoPOC PMPA
    Met. X:
    Figure US20050124583A1-20050609-C00031
    Met. Y:
    Figure US20050124583A1-20050609-C00032
    A =
    Figure US20050124583A1-20050609-C00033
  • Example 10 Plasma and PBMC Exposures Following Oral Administration of Prodrug Diastereomers to Beagle Dogs
  • The pharmacokinetics of GS 7340 were studied in dogs after oral administration of a 10 mg-eq/kg dose.
  • Formulations. The prodrugs were formulated as solutions in 50 mM citric acid within 0.5 hour prior to dose. All compounds used in the studies were synthesized by Gilead Sciences. The following lots were used:
    Amidate Amino Diastereo-
    GSI acid AA Ester isomer Lot Number
    GS-7340-2 Alanine i-Propyl Isomer A 1504-187-19
    GS-7339 Alanine i-Propyl Isomer B 1509-185-31
    GS7114 Alanine Ethyl Isomer A 1509-181-26
    GS7115 Alanine Ethyl Isomer B 1509-181-22
    GS7119 Glycine Ethyl Isomer A 1428-163-28
    GS7342 □-Aminobutyric Ethyl Isomer A 1509-191-12
    Acid
    GS7341 □-Aminobutyric Ethyl Isomer B 1509-191-7
    Acid
  • Dose Administration and Sample Collection. The in-life phase of this study was conducted in accordance with the recommendations of the “Guide for the Care and Use of Laboratory Animals” (National Institutes of Health publication 86-23) and was approved by an Institutional Animal Care and Use Committee. Fasted male beagle dogs (10±2 kg) were used for the studies. Each drug was administered as a single dose by oral gavage (1.5-2 ml/kg). The dose was 10 mg-equivalent of PMPA/kg. For PBMCs, blood samples were collected at 0 (pre-dose), 2, 8, and 24 h post-dose. For plasma, blood samples were collected at 0 (pre-dose), 5, 15, and 30 min, and 1, 2, 3, 4, 6, 8, 12 and 24 h post-dose. Blood (1.0 ml) was processed immediately for plasma by centrifugation at 2,000 rpm for 10 min. Plasma samples were frozen and maintained at 70° C. until analyzed.
  • Peripheral Blood Mononuclear Cell (PBMC) preparation. Whole blood (8 ml) drawn at specified time points was mixed in equal proportion with phosphate buffered saline (PBS), layered onto 15 ml of Ficoll-Paque solution (Pharmacia Biotech) and centrifuged at 400×g for 40 min. PBMC layer was removed and washed once with PBS. Formed PMBC pellet was reconstituted in 0.5 ml of PBS, cells were resuspended, counted using hemocytometer and maintained at 70° C. until analyzed. The number of cells multiplied by the mean single-cell volume was used in calculation of intracellular concentrations. A reported value of 200 femtoliters/cell was used as the resting PBMC volume (B. L. Robins, R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland, Antimicrob. Agents Chemother. 42, 612 (1998).
  • Determination of PMPA and Prodrugs in plasma and PBMCs. The concentration of PMPA in dog plasma samples was determined by derivatizing PMPA with chloroacetaldehyde to yield a highly fluorescent N1, N6-ethenoadenine derivative (L. Naesens, J. Balzarini, and E. De Clercq, Clin. Chem. 38, 480 (1992). Briefly, plasma (100 μl) was mixed with 200 μl acetonitrile to precipitate protein. Samples were then evaporated to dryness under reduced pressure at room temperature. Dried samples were reconstituted in 200 μl derivatization cocktail (0.34% chloroacetaldehyde in 100 mM sodium acetate, pH 4.5), vortexed, and centrifuged. Supernatant was then transferred to a clean screw-cap tube and incubated at 95° C. for 40 min. Derivatized samples were then evaporated to dryness and reconstituted in 100 μl of water for HPLC analysis.
  • Before intracellular PMPA could be determined by HPLC, the large amounts of adenine related ribonucleotides present in the PBMC extracts had to be removed by selective oxidation. We used a modified procedure of Tanaka et al (K. Tanaka, A. Yoshioka, S. Tanaka, and Y. Wataya, Anal. Biochem., 139, 35 (1984). Briefly, PBMC samples were mixed 1:2 with methanol and evaporated to dryness under reduced pressure. The dried samples were derivatized as described in the plasma assay. The derivatized samples were mixed with 20 μL of 1M rhamnose and 30 μL of 0.1M sodium periodate and incubated at 37° C. for 5 min. Following incubation, 40 μL of 4M methylamine and 20 μL of 0.5M inosine were added. After incubation at 37° C. for 30 min, samples were evaporated to dryness under reduced pressure and reconstituted in water for HPLC analysis.
  • No intact prodrug was detected in any PBMC samples. For plasma samples potentially containing intact prodrugs, experiments were performed to verify that no further conversion to PMPA occurred during derivatization. Prodrug standards were added to drug-free plasma and derivatized as described. There were no detectable levels of PMPA present in any of the plasma samples, and the projected % of conversion was less than 1%.
  • The HPLC system was comprised of a P4000 solvent delivery system with AS3000 autoinjector and F2000 fluorescence detector (Thermo Separation, San Jose, Calif.). The column was an Inertsil ODS-2 column (4.6×150 mm). The mobile phases used were: A, 5% acetonitrile in 25 mM potassium phosphate buffer with 5 mM tetrabutyl ammonium bromide (TBABr), pH 6.0; B, 60% acetonitrile in 25 mM potassium phosphate buffer with 5 mM TBABr, pH 6.0. The flow rate was 2 ml/min and the column temperature was maintained at 35° C. by a column oven. The gradient profile was 90% A/10% B for 10 min for PMPA and 65% A/35% B for 10 min for the prodrug. Detection was by fluorescence with excitation at 236 nm and emission at 420 nm, and the injection volume was 10 μl. Data was acquired and stored by a laboratory data acquisition system (PeakPro, Beckman, Allendale, N.J.).
  • Pharmacokinetic Calculations. PMPA and prodrug exposures were expressed as areas under concentration curves in plasma or PBMC from zero to 24 hours (AUC). The AUC values were calculated using the trapezoidal rule.
  • Plasma and PBMC Concentrations. The results of this study is shown in FIGS. 2 and 3. FIG. 2 shows the time course of GS 7340-2 metabolism summary of plasma and PBMC exposures following oral administration of pure diastereoisomers of the PMPA prodrugs.
  • The bar graph in FIG. 2 shows the AUC (0-24 h) for tenofovir in dog PBMCs and plasma after administration of PMPA s.c., TDF and amidate ester prodrugs. All of the amidate prodrugs exhibited increases in PBMC exposure. For example, GS 7340 results in a ˜21-fold increase in PBMC exposure as compared to PMPA s.c. and TDF; and a 6.25-fold and 1.29-fold decrease in plasma exposure, respectively.
  • These data establish in vivo that GS 7340 can be delivered orally, minimizes systemic exposure to PMPA and greatly enhances the intracellular concentration of PMPA in the cells primarily responsible for HIV replication.
    TABLE 6
    PMPA Exposure in PBMC and Plasma from Oral Prodrugs of PMPA in Dogs
    PBMC/Plasma
    PMPA AUC in Plasma PMPA AUC in PBMC Prodrug Exposure
    GS# Moiety Mean StDev N Mean StDev N in Plasma Ratio
    GS-7114 Mono-Ala-Et-A 5.8 0.9 2 706 331 5 YES 122
    GS-7115 Mono-Ala-Et-B 6.6 1.5 2 284 94 5 YES 43
    GS-7340-2 Mono-Ala-iPr-A 5.0 1.1 5 805 222 5 YES 161
    GS-7339 Mono-Ala-iPr-A 6.4 1.3 2 200 57 5 YES 31
    GS-7119 Mono-Gly-Et-A 6.11 1.86 2 530 304 5 YES 87
    GS-7342 Mono-ABA-Et-A 4.6 1.2 2 1060 511 5 YES 230
    GS7341 Mono-ABA-Et-B 5.8 1.4 2 199 86 5 YES 34
  • Example 11 Biodistribution of GS-7340
  • As part of the preclinical characterization of GS-7340, its biodistribution in dogs was determined. The tissue distribution of GS-7340 (isopropyl alaninyl monoamidate, phenyl monoester of tenofovir) was examined following oral administration to beagle dogs. Two male animals were dosed orally with 14C=GS-7340 (8.85 mg-equiv. of PMPA/kg, 33.2 μCi/kg; the 8-carbon of adenine is labeled) in an aqueous solution (50 mM citric acid, pH 2.2). Plasma and peripheral blood mononuclear cells (PBMCs) were obtained over the 24-hr period. Urine and feces were cage collected over 24 hr. At 24 h after the dose, the animals were sacrificed and tissues removed for analysis. Total radioactivity in tissues was determined by oxidation and liquid scintillation counting.
  • The biodistribution of PMPA after 24 hours after a single oral dose of radiolabelled GS 7340 is shown in Table 4 along with the data from a previous study with TDF (GS-4331). In the case of TDF, the prodrug concentration in the plasma is below the level of assay detection, and the main species observed in plasma is the parent drug. Levels of PMPA in the lymphatic tissues, bone marrow, and skeletal muscle are increased 10-fold after administration of GS-7340.
  • Accumulation in lymphatic tissues is consistent with the data observed from the PBMC analyses, since these tissues are composed primarily of lymphocytes. Likewise, accumulation in bone marrow is probably due to the high percentage of lymphocytes (70%) in this tissue.
    TABLE 7
    Excretion and Tissue Distribution of Radiolabelled GS-7340 in Dogs
    (Mean, N = 2) Following an Oral Dose at 10 mg-eq. PMPA/kg.
    Tissue Conc.
    GS-4331 GS-7340 Ratio of GS
    Conc. Conc. 7340
    Tissue/Fluid % Dose (ug-eq/g) % Dose (ug-eq/g) to GS-4331
    Liver 12.40 38.30 16.45 52.94 1.4
    Kidney 4.58 87.90 3.78 80.21 0.9
    Lungs 0.03 0.53 0.34 4.33 8.2
    Iliac Lymph Nodes 0.00 0.51 0.01 5.42 10.6
    Axillary Lymph Nodes 0.00 0.37 0.01 5.54 14.8
    Inguinal Lymph Nodes 0.00 0.28 0.00 4.12 15.0
    Mesenteric Lymph 0.00 1.20 0.04 6.88 5.7
    Thyroid Gland 0.00 0.30 0.00 4.78 15.8
    Pituitary Gland 0.00 0.23 0.00 1.80 7.8
    Salivary Gland (L + R) 0.00 0.45 0.03 5.54 12.3
    Adrenal Gland 0.00 1.90 0.00 3.47 1.8
    Spleen 0.00 0.63 0.17 8.13 12.8
    Pancreas 0.00 0.57 0.01 3.51 6.2
    Prostate 0.00 0.23 0.00 2.14 9.1
    Testes (L + R) 0.02 1.95 0.02 2.01 1.0
    Skeletal Muscle 0.00 0.11 0.01 1.12 10.1
    Heart 0.03 0.46 0.15 1.97 4.3
    Femoral Bone 0.00 0.08 0.00 0.28 3.5
    Bone Marrow 0.00 0.20 0.00 2.05 10.2
    Skin 0.00 0.13 0.00 0.95 7.2
    Abdominal fat 0.00 0.16 0.00 0.90 5.8
    Eye (L + R) 0.00 0.06 0.00 0.23 3.7
    Brain 0.00 <LOD 0.00 <LOD n.d.
    Cerebrospinal Fluid 0.00 <LOD 0.00 0.00 n.d.
    Spinal Cord 0.00 <LOD 0.00 0.04 n.d.
    Stomach 0.11 1.92 0.26 2.68 1.4
    Jejunum 1.34 3.01 0.79 4.16 1.4
    Duodenum 0.49 4.96 0.44 8.77 1.8
    Ileum 0.01 0.50 0.16 4.61 9.2
    Large Intestine 1.63 5.97 2.65 47.20 7.9
    Gall bladder 0.00 3.58 0.04 25.02 7.0
    Bile 0.00 9.63 0.22 40.48 4.2
    Feces 40.96 n.d. 0.19 n.d. n.a.
    Total GI Tract Contents 5.61 n.d. 21.64 n.d. n.a.
    Urine 23.72 n.d. 14.73 n.d. n.a.
    Plasma at 24 h 0.00 0.20 0.00 0.20 1.0
    Plasma at 0.25 h n.a. 3.68 n.a. 3.48 0.9
    PBMC* 0.00 n.d. 0.00 63.20 n.d.
    Whole Blood 0.00 0.85 0.16 0.20 0.2
    Total Recovery 81.10 68.96

    Calculated using typical recovery of 15 × 106 cells total, and mean PBMC volume of 0.2 picoliters/cell

    n.s. = no sample,

    n.a. = not applicable,

    n.d. = not determined.

Claims (4)

1. A fumarate salt of a nucleotide analog compound according to structural formula (Ia):
Figure US20050124583A1-20050609-C00034
that comprises at least about 60% by weight a diastereomer according to structure (Ib):
Figure US20050124583A1-20050609-C00035
2. The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 80% by weight the diastereomer of structure (Ib).
3. The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 95% by weight the diastereomer of structure (Ib).
4. The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 99% by wieight the diastereomer of structure (Ib).
US11/031,250 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues Abandoned US20050124583A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US22002100P true 2000-07-21 2000-07-21
US09/909,560 US20020119443A1 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/354,207 US20030219727A1 (en) 2000-07-21 2003-01-28 Prodrugs of phosphonate nucleotide analogues
US10/798,692 US7390791B2 (en) 2000-07-21 2004-03-11 Prodrugs of phosphonate nucleotide analogues
US11/031,250 US20050124583A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/031,250 US20050124583A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/798,692 Continuation US7390791B2 (en) 2000-07-21 2004-03-11 Prodrugs of phosphonate nucleotide analogues

Publications (1)

Publication Number Publication Date
US20050124583A1 true US20050124583A1 (en) 2005-06-09

Family

ID=22821718

Family Applications (10)

Application Number Title Priority Date Filing Date
US09/909,560 Abandoned US20020119443A1 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/333,107 Abandoned US20040018150A1 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/354,207 Abandoned US20030219727A1 (en) 2000-07-21 2003-01-28 Prodrugs of phosphonate nucleotide analogues
US10/785,497 Abandoned US20060024659A1 (en) 2000-07-21 2004-02-24 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/798,692 Active 2022-05-07 US7390791B2 (en) 2000-07-21 2004-03-11 Prodrugs of phosphonate nucleotide analogues
US11/031,228 Abandoned US20050159392A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US11/031,250 Abandoned US20050124583A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US11/031,252 Abandoned US20050124585A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US11/031,251 Abandoned US20050124584A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US12/110,829 Active 2022-02-02 US7803788B2 (en) 2000-07-21 2008-04-28 Prodrugs of phosphonate nucoleotide analogues

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US09/909,560 Abandoned US20020119443A1 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/333,107 Abandoned US20040018150A1 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/354,207 Abandoned US20030219727A1 (en) 2000-07-21 2003-01-28 Prodrugs of phosphonate nucleotide analogues
US10/785,497 Abandoned US20060024659A1 (en) 2000-07-21 2004-02-24 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US10/798,692 Active 2022-05-07 US7390791B2 (en) 2000-07-21 2004-03-11 Prodrugs of phosphonate nucleotide analogues
US11/031,228 Abandoned US20050159392A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/031,252 Abandoned US20050124585A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US11/031,251 Abandoned US20050124584A1 (en) 2000-07-21 2005-01-06 Prodrugs of phosphonate nucleotide analogues
US12/110,829 Active 2022-02-02 US7803788B2 (en) 2000-07-21 2008-04-28 Prodrugs of phosphonate nucoleotide analogues

Country Status (35)

Country Link
US (10) US20020119443A1 (en)
EP (3) EP1301519B1 (en)
JP (4) JP4651264B2 (en)
KR (2) KR100749160B1 (en)
CN (2) CN100402539C (en)
AP (1) AP1466A (en)
AU (3) AU8294101A (en)
BG (1) BG66037B1 (en)
BR (2) BRPI0112646B1 (en)
CA (3) CA2725819C (en)
CY (1) CY1119411T1 (en)
CZ (2) CZ304734B6 (en)
DK (2) DK2682397T3 (en)
EA (1) EA004926B1 (en)
EE (1) EE05366B1 (en)
ES (2) ES2627903T3 (en)
HK (1) HK1054238A1 (en)
HR (2) HRP20030047B1 (en)
HU (1) HU230960B1 (en)
IL (1) IL153658D0 (en)
IS (1) IS2985B (en)
LT (2) LT2682397T (en)
LU (1) LU93029I2 (en)
MX (1) MXPA03000587A (en)
NL (1) NL300803I2 (en)
NO (5) NO336718B1 (en)
NZ (3) NZ535408A (en)
OA (1) OA12393A (en)
PL (1) PL213214B1 (en)
PT (2) PT2682397T (en)
SI (2) SI2682397T1 (en)
TR (1) TR200300055T2 (en)
UA (1) UA75889C2 (en)
WO (1) WO2002008241A2 (en)
ZA (1) ZA200210271B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
US8749576B2 (en) 2004-05-14 2014-06-10 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
WO2016205141A1 (en) * 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213214B1 (en) * 2000-07-21 2013-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
CA2466301A1 (en) * 2001-11-14 2003-10-23 Biocryst Pharmaceuticals, Inc. Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US20070010489A1 (en) 2002-04-26 2007-01-11 Arimilli Murty N Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
PL408254A1 (en) * 2003-01-14 2014-07-21 Gilead Sciences Inc. Compositions and methods used in combination for antiviral therapy
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
AU2004233897A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
NZ542342A (en) 2003-04-25 2009-05-31 Gilead Sciences Inc Antiviral phosphonate analogs
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CN101410120A (en) * 2003-04-25 2009-04-15 吉里德科学公司 Antiinflammatory phosphonate compound
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
BRPI0418031A (en) * 2003-12-22 2007-04-17 Gilead Sciences Inc kinase inhibitors phosphonate substituted
US7273717B2 (en) * 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US20080287471A1 (en) * 2003-12-22 2008-11-20 Maria Fardis 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
EP1716162B1 (en) * 2003-12-30 2010-08-18 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
ES2334149T3 (en) * 2004-01-21 2010-03-05 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting virus MMTV-like involved in breast cancer and primary biliary cirrhosis.
AU2005254940A1 (en) 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
JP2008535862A (en) 2005-04-08 2008-09-04 キメリクス,インコーポレイテッド Compounds for the treatment of poxvirus infections, the compositions and methods
EP1865967A4 (en) * 2005-04-08 2011-02-09 Chimerix Inc Compounds, compositions and methods for the treatment of viral infections and other medical disorders
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN100396689C (en) 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 Tenoforv monoester compounds with HIV-1/HBV virus copying inhibiting activity
PT2020996E (en) 2006-05-16 2012-02-20 Gilead Sciences Inc Method and compositions for treating hematological malignancies
EP2046792B1 (en) * 2006-07-12 2015-02-25 Mylan Laboratories Limited Process for the preparation of tenofovir
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8105489B2 (en) * 2007-06-26 2012-01-31 The University Of Wyoming Research Corporation Treatment and prevention systems for acid mine drainage and halogenated contaminants
EP3085377A1 (en) * 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
KR20110017863A (en) * 2008-04-25 2011-02-22 씨아이피엘에이 엘티디. Crystalline form of tenofovir disoproxil and a process for its preparation
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2476690A1 (en) * 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
BRPI0915878A2 (en) * 2008-07-08 2015-11-03 Gilead Sciences Inc salts or hydrates of HIV inhibitory compounds, their use and pharmaceutical composition comprising
AR074882A1 (en) 2008-12-23 2011-02-16 Pharmasset Inc Nucleoside
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
AR074977A1 (en) 2008-12-23 2011-03-02 Pharmasset Inc Purine nucleoside synthesis
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CL2011000718A1 (en) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Process for the preparation of enantiomeric phosphorus compounds.
CN102917585A (en) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EA025311B1 (en) * 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
JP5969471B2 (en) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド The methods and compounds for treating Paramyxoviridae virus infection
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
KR101880724B1 (en) 2010-12-10 2018-08-17 시그마팜 래보러토리즈, 엘엘씨 Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012154698A2 (en) * 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
EP3450438A1 (en) 2011-05-19 2019-03-06 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
UY34262A (en) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarate alafenamida tenofovir, their compositions, methods of preparation, methods for treating viral infections and their use for preparing medicinal products
AU2014271320B2 (en) * 2011-08-16 2017-02-23 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
TWI613211B (en) 2011-10-07 2018-02-01 Gilead Sciences Inc Methods for preparing anti-viral nucleotide analogs
AU2016228317B2 (en) * 2011-10-07 2018-07-19 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
AU2014215976B2 (en) * 2011-10-07 2016-06-30 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
WO2013095684A1 (en) 2011-12-22 2013-06-27 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN104105484A (en) 2012-02-03 2014-10-15 吉联亚科学公司 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CN103665043B (en) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 One kind of tenofovir prodrugs and the use in medicine
GB201215696D0 (en) * 2012-09-03 2012-10-17 Ithemba Pharmaceuticals Pty Ltd A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
WO2014068265A1 (en) * 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102899327B (en) * 2012-11-06 2014-06-11 清华大学深圳研究生院 Antiviral small nucleic acid and temperature-sensitive type gel preparation and application thereof
MX2015006191A (en) * 2012-11-16 2015-08-10 Merck Sharp & Dohme Purine inhibitors of human phosphatidylinositol 3-kinase delta.
CN103848868B (en) * 2012-12-04 2017-04-12 蚌埠丰原涂山制药有限公司 The method of preparing tenofovir
CN103848869B (en) * 2012-12-04 2016-12-21 上海医药工业研究院 The method of preparing tenofovir
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN104072539B (en) * 2013-03-25 2017-03-29 安徽贝克联合制药有限公司 Tenofovir bis (4-acetylamino phenol group) esters and their preparation and use
EP3000898A4 (en) * 2013-05-21 2016-07-06 Hitgen Ltd Drug target capturing method
IN2013MU01967A (en) 2013-06-07 2015-06-12 Cipla Limited "an efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine"
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
EP2860185A1 (en) 2013-10-09 2015-04-15 Zentiva, k.s. An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof
IN2013CH05455A (en) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd A recycling process for preparing tenofovir alafenamide diastereomers
IN2014MU00118A (en) 2014-01-14 2015-08-28 Mylan Laboratories Ltd. Process for the preparation of tenofovir alafenamide and its pharmaceutically acceptable salts
TW201609780A (en) 2014-01-15 2016-03-16 Gilead Sciences Inc Solid forms of tenofovir
CN104804042B (en) * 2014-01-24 2018-01-19 齐鲁制药有限公司 Phosphonate nucleotide compounds, pharmaceutical compositions, preparation and use
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
CN105814068B (en) * 2014-02-27 2017-08-04 四川海思科制药有限公司 One substituted amino phosphate derivatives, their preparation and their use
CN105001262B (en) * 2014-04-18 2017-09-01 四川海思科制药有限公司 Aryl-substituted phosphoramide derivatives and their use in medicine
CN105518011B (en) * 2014-04-21 2018-07-27 四川海思科制药有限公司 Preparation of amino derivatives and phosphate-based preparation of intermediates and intermediates
CN105085571A (en) * 2014-05-20 2015-11-25 四川海思科制药有限公司 Tenofovir alafenamide compound, preparation method and purpose thereof
WO2015197006A1 (en) * 2014-06-25 2015-12-30 四川海思科制药有限公司 Substituted amino acid thioester compound, and composition and application thereof
CN106687118A (en) 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof
KR101703257B1 (en) 2014-09-30 2017-02-06 한미정밀화학주식회사 Preparation method for (r)-9-[2-(phosphonomethoxy)propyl]adenine with high purity
TW201629076A (en) 2014-10-29 2016-08-16 Gilead Sciences Inc Methods for treating filoviridae virus infections
CN108191913A (en) * 2014-11-12 2018-06-22 四川海思科制药有限公司 Tenofovir alafenamide crystal form a and preparation method thereof
CN104558036A (en) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 Tenofovir alafenamide hemi-fumarate crystal form and preparation method thereof
KR101703258B1 (en) 2014-12-30 2017-02-06 한미정밀화학주식회사 Preparation method for (r)-9-[2-(phosphonomethoxy)propyl]adenine with high purity
JP2018502118A (en) 2015-01-03 2018-01-25 マイラン・ラボラトリーズ・リミテッドMylan Laboratories Limited Amorphous hemifumarate Tenofovir Ala Fe cyanamide and processes for preparing the premix
CN106188139A (en) 2015-05-29 2016-12-07 江苏天士力帝益药业有限公司 Tenofovir monobenzyl phosphoric acid amide prodrug, as well as preparation method and application thereof
CZ2015384A3 (en) 2015-06-05 2016-12-14 Zentiva, K.S. Tenofovir alafenamide solid forms
AU2016305941B2 (en) 2015-08-10 2018-11-15 Merck Sharp And Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
TWI616452B (en) * 2015-08-26 2018-03-01
TWI620754B (en) * 2015-08-26 2018-04-11
TWI616453B (en) * 2015-08-27 2018-03-01
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
MX2018003161A (en) 2015-09-16 2018-05-17 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections.
AU2016354007A1 (en) 2015-11-09 2018-05-10 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
EP3411378A1 (en) 2016-02-02 2018-12-12 Sandoz AG Crystalline forms of tenofovir alafenamide monofumarate
CN108350007A (en) * 2016-03-01 2018-07-31 深圳市塔吉瑞生物医药有限公司 Substituted adenine compound and pharmaceutical composition thereof
CZ2016156A3 (en) 2016-03-17 2017-09-27 Zentiva, K.S. The method of preparation of diastereomerically pure Tenofovir Alafenamide or its salts
WO2017211325A1 (en) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 New crystal form of tenofovir alafenamide salt, preparation method and use thereof
CN106543227B (en) * 2016-06-20 2018-02-02 杭州和泽医药科技有限公司 One kind of a phosphonate prodrug derivatives and its application in medicine adenine
WO2017221189A1 (en) * 2016-06-22 2017-12-28 Laurus Labs Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
CN106317116A (en) * 2016-08-19 2017-01-11 张红利 Phosphamide nucleosides compound, pharmaceutically acceptable salt and application thereof, and pharmaceutical composition
CN106380484A (en) * 2016-08-29 2017-02-08 杭州百诚医药科技股份有限公司 New crystal form of tenofovir alafenamide and preparation method thereof
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
CN106565785A (en) * 2016-11-09 2017-04-19 周雨恬 Nucleoside phosphoramidate type compound with HBV/HIV resistance activity and salt and application of nucleoside phosphoramidate type compound
US20180179208A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
WO2018118826A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TW201831190A (en) 2017-01-31 2018-09-01 美商基利科學股份有限公司 Alternatively alafenamide (tenofovir alafenamide) of Form
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2647576C1 (en) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Cyclobutyl (s)-2-[[[r)-2-(6-aminopurin-9-yl)-1-methyl-etoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, method of their production and application
RU2659388C1 (en) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application
CN106866739B (en) * 2017-03-10 2018-11-02 华东师范大学 A process for preparing (r) -1- (6- -9h--amino-purin-9-yl) 2- phenyl ester
WO2018175325A1 (en) 2017-03-20 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv post-exposure prophylaxis
CN107266499B (en) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 A kind of antiviral compound and preparation method thereof
WO2019003251A1 (en) 2017-06-30 2019-01-03 Cipla Limited Pharmaceutical compositions
WO2019021319A1 (en) 2017-07-27 2019-01-31 Cipla Limited Pharmaceutical compositions
CN107522743A (en) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 Industrialized continuous production method of hemifumarate tenofovir alafenamide
WO2019084020A1 (en) 2017-10-24 2019-05-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
WO2019130354A1 (en) 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5053215A (en) * 1988-05-26 1991-10-01 University Of Florida NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
JP2648516B2 (en) 1989-07-27 1997-09-03 ダイセル化学工業株式会社 Separation of stereoisomers
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
JP2925753B2 (en) 1990-02-23 1999-07-28 ダイセル化学工業株式会社 The method of separating optical isomers
DE69110528D1 (en) * 1990-04-20 1995-07-27 Acad Of Science Czech Republic Chiral 2- (phosphonomethoxy) propyl guanines as antiviral agents.
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (en) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, processes of their preparation and use
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
WO1992002511A1 (en) 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
DK0481214T3 (en) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prodrugs of phosphonates
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CZ284678B6 (en) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-p-toluenesulfonyloxypropanes, process of their preparation and use
JP3010816B2 (en) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 Method for recovering optical isomers and a solvent in optical resolution, circulation use of solvents, and re-usage of the optical isomers
US5498752A (en) 1991-08-22 1996-03-12 Daicel Chemical Industries, Ltd. Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution
AT151432T (en) 1991-10-11 1997-04-15 Acad Of Science Czech Republic Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IL106998D0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
AU690587B2 (en) * 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
WO1997024361A1 (en) 1995-12-29 1997-07-10 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
AT245161T (en) * 1995-05-26 2003-08-15 Genta Inc A process for the synthesis of organophosphorus compounds
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
BR9811552A (en) 1997-07-25 2000-08-29 Gilead Sciences Inc nucleotide analogs Compositions
WO1999005150A1 (en) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1037649B1 (en) * 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
DE69900841T2 (en) * 1998-01-23 2002-10-02 Newbiotics Inc By enzyme catalysis obtained therapeutic substances.
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
JP2002518521A (en) * 1998-06-20 2002-06-25 ワシントン・ユニバーシティ Membrane permeable peptide complexes for medical image analysis, diagnosis and treatment
US6169879B1 (en) * 1998-09-16 2001-01-02 Webtv Networks, Inc. System and method of interconnecting and using components of home entertainment system
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
TWI230618B (en) 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
PL213214B1 (en) 2000-07-21 2013-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US20020119433A1 (en) * 2000-12-15 2002-08-29 Callender Thomas J. Process and system for creating and administering interview or test

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8749576B2 (en) 2004-05-14 2014-06-10 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
WO2016205141A1 (en) * 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
US9777028B2 (en) 2015-06-17 2017-10-03 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
US10155781B2 (en) 2015-06-17 2018-12-18 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
AU2016277859B2 (en) * 2015-06-17 2019-08-01 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide

Also Published As

Publication number Publication date
NO2016006I1 (en) 2016-04-19
CA2416757A1 (en) 2002-01-31
CN1443189A (en) 2003-09-17
NO2016006I2 (en) 2016-04-19
JP2011140506A (en) 2011-07-21
PT1301519E (en) 2015-06-11
ES2536972T3 (en) 2015-06-01
US20050124584A1 (en) 2005-06-09
US20030219727A1 (en) 2003-11-27
US7803788B2 (en) 2010-09-28
NO20131717L (en) 2003-03-20
CN100402539C (en) 2008-07-16
NO336718B1 (en) 2015-10-26
MXPA03000587A (en) 2004-04-05
SI1301519T1 (en) 2015-07-31
CA2725819A1 (en) 2002-01-31
JP5111551B2 (en) 2013-01-09
EA200300188A1 (en) 2003-06-26
PL213214B1 (en) 2013-01-31
CY1119411T1 (en) 2018-03-07
NZ523438A (en) 2005-02-25
CA2416757C (en) 2011-02-15
DK1301519T3 (en) 2015-05-26
NO20150909L (en) 2003-03-20
ZA200210271B (en) 2003-12-31
DK2682397T3 (en) 2017-06-19
BR0112646A (en) 2003-06-24
CN1291994C (en) 2006-12-27
HRP20160074A8 (en) 2016-07-29
AU2005225039B2 (en) 2008-09-25
JP2009062383A (en) 2009-03-26
JP4651264B2 (en) 2011-03-16
JP5063554B2 (en) 2012-10-31
LU93029I2 (en) 2016-06-14
KR20030022295A (en) 2003-03-15
BRPI0112646B1 (en) 2017-10-17
KR100767432B1 (en) 2007-10-17
BG107572A (en) 2003-11-28
EP3235823A1 (en) 2017-10-25
WO2002008241A3 (en) 2002-08-29
CZ304886B6 (en) 2015-01-07
PT2682397T (en) 2017-05-31
US20050159392A1 (en) 2005-07-21
TR200300055T2 (en) 2004-12-21
AU2001282941B2 (en) 2006-04-27
IS6689A (en) 2003-01-17
KR20060105807A (en) 2006-10-11
HRP20160074A2 (en) 2016-03-11
HU230960B1 (en) 2019-06-28
US20020119443A1 (en) 2002-08-29
EP1301519B1 (en) 2015-02-25
LT2682397T (en) 2017-06-12
EP2682397B1 (en) 2017-04-19
EP2682397A1 (en) 2014-01-08
CA2893174A1 (en) 2002-01-31
PL360490A1 (en) 2004-09-06
OA12393A (en) 2006-04-18
CA2725819C (en) 2015-09-22
JP2004504402A (en) 2004-02-12
JP2010174033A (en) 2010-08-12
NO20030270L (en) 2003-03-20
KR100749160B1 (en) 2007-08-14
EP1301519A2 (en) 2003-04-16
ES2627903T3 (en) 2017-08-01
EA004926B1 (en) 2004-10-28
AU2001282941C1 (en) 2016-12-22
CZ304734B6 (en) 2014-09-10
CZ2003413A3 (en) 2003-12-17
NZ535408A (en) 2006-09-29
NO20030270D0 (en) 2003-01-20
US20080227754A1 (en) 2008-09-18
US20040018150A1 (en) 2004-01-29
WO2002008241A2 (en) 2002-01-31
NZ536942A (en) 2006-03-31
CN1706855A (en) 2005-12-14
NL300803I2 (en) 2016-06-30
HRP20030047A2 (en) 2007-08-31
SI2682397T1 (en) 2017-08-31
IS2985B (en) 2017-09-15
EE05366B1 (en) 2010-12-15
UA75889C2 (en) 2006-06-15
AP1466A (en) 2005-09-22
US7390791B2 (en) 2008-06-24
BG66037B1 (en) 2010-11-30
AU8294101A (en) 2002-02-05
HU0301307A2 (en) 2003-09-29
US20060024659A1 (en) 2006-02-02
EE200300029A (en) 2004-10-15
AP200302724A0 (en) 2003-06-30
NO20120466L (en) 2003-03-20
LTC1301519I2 (en) 2017-06-12
HU0301307A3 (en) 2005-12-28
US20050009043A1 (en) 2005-01-13
AU2005225039A1 (en) 2005-11-10
IL153658D0 (en) 2003-07-06
US20050124585A1 (en) 2005-06-09
HRP20030047B1 (en) 2016-02-26
HK1054238A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
Cui et al. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.
Pai et al. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.
Holý et al. Structure− antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy) ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base
JP2610782B2 (en) Radiant energy detecting method and system
EP0642528B1 (en) Phosphotriester-type biologically active compounds
EP2432792B1 (en) And process for the preparation of n-[(2&#39;r)-2&#39;-deoxy-2&#39;-fluoro-2&#39;-methyl-p-phenyl-5&#39;-uridylyl]-l-alanine 1-methylethyl ester
US7307065B2 (en) 2′-Fluoronucleosides
KR100974917B1 (en) 3&#39;- or 2&#39;-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6617437B1 (en) Pyrimidine derivatives for labeled binding partners
US5872107A (en) Treatment of urogenital cancer with boron neutron capture therapy
EP1233770B1 (en) Phosphonate compounds
KR100691737B1 (en) ?-L-2&#39;-Deoxy-nucleosides for the treatment of hepatitis B
EP2552930B1 (en) Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
AU600002B2 (en) N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
US4963662A (en) Fluorinated nucleosides and method for treating retrovirus infections therewith
EP0821690B1 (en) Nucleotide analogues for the treatment of viral infections
EP0710667B1 (en) Modified oligonucleotides, their preparation and their use
EP0663922B1 (en) Infra-red dye-labelled nucleotides and their use in nucleic acid detection
US5151507A (en) Alkynylamino-nucleotides
EP0719273B1 (en) Nucleotide analogs
Abraham et al. Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2 ‘-deoxyuridine and 1-β-arabinofuranosylcytosine: Evidence of phosphoramidase activity
DE69827013T2 (en) base analogues
Harnden et al. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl) but-1-yl] guanine (BRL 39123) with improved gastrointestinal absorption properties
Puech et al. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process
US6057305A (en) Antiretroviral enantiomeric nucleotide analogs

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION